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ABSTRACT 
 
Total Syntheses of β-Lactone Containing Natural Products: Total Synthesis of 
Belactosin C and Synthetic Studies toward Spongiolactone. (December 2008) 
Sung Wook Cho, B.S., Sogang University, Korea; M.S., Sogang University, Korea 
Chair of Advisory Committee: Dr. Daniel Romo 
 
The recently isolated bacterial metabolites, belactosins A-C from a fermentation 
broth of Streptomyces sp. UCK14, uniquely contain a β-lactone dipeptide motif and 
exhibit anticancer activities. The enantioselective synthesis of (-)-belactosin C and 
derivatives was accomplished in a concise manner employing the tandem, Mukaiyama 
aldol-lactonizaton (TMAL) process and test their bioactivities. . One approach involved 
a distal double diastereoselective TMAL reaction with a dipeptide glyoxamide, whereas 
a second approach involved amide coupling of a dipeptide with a β-lactone carboxylic 
acid, obtained via the TMAL process employing a chiral silyl ketene acetal. Enzymatic 
assays showed that the belactosins act as the dual inhibitors of the proteasome and the 
thioesterase domain of fatty acid synthase. 
Spongiolactone which uniquely contains a cyclopentyl-fused β-lactone was 
isolated in 1986 from Spongi-onellagracilis No biological activity have been reported 
for this compound;  however, the acylating potential of the resident β-lactone warrants 
screening for potential activity. After many setbacks in the synthesis of spongiolactone, 
significant progress has been made. Importantly, NCAL process also enabled a concise 
 iv
construction of [3.2.0]-bicyclo β-lactone, which is the key structure in the 
spongiolactone synthesis and only a few steps remained to complete the synthesis. 
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CHAPTER I ! 
INTRODUCTION: THE SYNTHESES OF β-LACTONE CONTAINING 
NATURAL PRODUCTS 
 
β-lactones are useful synthetic intermediates since they are masked aldol products 
with inherent reactivity making them useful synthons in natural and unnatural product 
synthesis. 1  However, there are relatively few enantioselective methods for β-lactone 
synthesis. Recent studies including those emanating from our group have begun to 
address this paucity of methods. Furthermore, the total syntheses of β-lactone containing 
natural products have only recently begun to appear.  
In this review chapter, recent syntheses of β-lactone containing natural products 
since 1995, when this topic was last reviewed will be described. In addition, β-lactone 
containing natural products that have been isolated but not yet synthesized will also be 
described. 
 
A. Previously Synthesized a β-Lactone Containing Natural Products  
To date there are several reports about various natural products syntheses containing 
β-lactone including lipstatin 1.1, (−)-panclicin D2 1.2,3 tetrahydrolipstatin(orlistat) 1.3,4 
valilactone 1.4, ebelactone A 1.5,5 norcadiolactone 1.6, vibralactone 1.7, omuralide 1.8,  
                                                
This dissertation follows the style and format of Journal of the American Chemical 
Society. 
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Figure 1.1. Previously Synthesized Natural Products Containing a β-Lactone 
 
salinosporamide A 1.9 and cinnabaramide A 1.10,6 (Figure 1.1). 
Lipstatin 1.1 was isolated from Streptomyces toxytricini, and the structure of 
lipstatin 1.1 was determined by a combination of spectroscopic and chemical methods,7 
and later confirmed by chemical synthesis.8  Lipstatin 1.1 features two linear carbon 
chains of six and thirteen atoms, respectively, affixed to a β-lactone ring. Structural 
analysis revealed a striking similarity between lipstatin and esterastin. Also ebelactone 
1.5, valilactone 1.4 and the panclicins have similar structures. The total synthesis of 
3 
lipstatin 1.1 from (S)-N-formyl-leucine and dimethyl-(S)-(−)-malate was described 
(Scheme 1.1). The diastereoselective Lewis acid-catalyzed [2 + 2] cycloaddition with 
silylketene 1.12 and dienal 1.11 delivered a mixture of four diastereomers 1.13a-d. O-
desilylation with HF followed by C-desilylation using TBAF delivered 2-oxetanone 1.15, 
which was isolated by column chromatography on silica gel. Finally, esterfication of the 
hydroxyl-2-oxetenone 1.15 with (S)-N-formylleucine under Misunobu condition 
delivered (-) lipstatin 1.1. 
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Panclicins are novel pancreatic lipase inhibitors isolated from Streptomyces sp. NR 
0619. Panclicins structures contain a β-lactone with two alkyl chains, one of which has 
N-formylalanyloxy or N-formylglycyloxy substituent. (−)-Panclicin D 1.2 synthesis was 
reported in 1997 by our group using a substrate controlled diastereoselective tandem 
Mukaiyama aldol lactonization (TMAL) process (Scheme 1.2). The TMAL process 
4 
using ketene acetal 1.18 and β-Silyloxy aldehyde 1.17 delivered the required β-lactone 
1.19 with good diastereoselectivity. The synthesis was completed by silyl deprotection 
with aqueous HF followed by inversion of the corresponding alcohol using Mitsunobu 
conditions to give (−)-panclicin D 1.2 in 20% overall yield from n-octanal 1.16.  
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Tetrahydrolipstatin 1.3, a reduced form of lipstatin, is an inhibitor of the thioesterase 
domain of fatty acid synthase (FAS), an enzyme associated with tumor cell 
proliferation.9 Due to the significant activity of tetrahydrolipstatin 1.3, a number of 
approaches have been reported for their synthesis.10 Recently, Kumaraswamy reported 
the total synthesis of (-)-tetrhydrolipstatin using a directed aldol reaction with 
Oppolzer’s sultam as the key step (Scheme 1.3). Acylsultam 1.20 was treated with TiCl4, 
and the sultam enolate was quenched with benyloxypropanal to deliver aldol adduct 1.21 
(4:5,<7:>93). After several steps, β-hydroxy acid 1.23 underwent lactonization with 
BOPCl to furnish the β-lactone in 75% yield. After debenzylation, DCC coupling with 
(S)-N-formylleucine delivered Tetrahydrolipstatin 1.3 
5 
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Our group also reported a convergent, “second generation” strategy toward (−)–
panclicin D derivatives that delivered easy access to Tetrahydrolipstatin (orlistat), 
valilactone and several congeners (Figure 1.2). Biological testing including inhibition 
studies of thioesterase domain of fatty acid synthase (FAS) were reported for orlistat and 
its derivatives.  
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Figure 1.2 Second Generation Strategy to Orlistat 
6 
 
Ebelactone A 1.5 is known to inhibitor esterases, lipases, and N-formylmethionone 
aminopeptidases located on the cellular membrane of various kinds of cells. In 1990, 
Paterson reported the total synthesis of ebelactone A, relying on aldol condensations and 
a Claisen rearrangement. However, it’s linear nature of the synthesis and poor 
diastereoselectivity for the aldol reaction were drawbacks.  Recently, Mandal reported 
ebelactone A synthesis using a subsequent Suzuki-Miyuara cross-coupling reaction 
(Figure 1.3) 
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Figure 1.3 Retrosynthesis of ebelactone A 
 
The masked β-lactone was synthesized by an Evan’s syn-aldol reaction between N-
propyl oxazolidinone 1.28 and α-benzyloxyacetaldehyde to afford the syn-aldol product 
1.29 in 95% yield as a single diastereomer (Scheme 1.4). 
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Norcardiolactone 1.6 is a simple β-lactone isolated by Mikami in 1999 from 
pathogenic Nocardia strains. During preliminary tests, it showed moderate narrow 
spectrum activity against gram-positive bacteria. Norcardiolactone 1.6 was synthesized 
by using a Crimmin’s asymmetric aldolization (Scheme 1.5). 
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Omuralide, salinosporamide A and their derivatives are hot molecules as they 
show potent proteasome inhibition ability with high target specificity. The synthetic 
efforts toward these have been reviewed recently.11 
The first total synthesis of salinosporamide A (1.9) was also described by Corey 
(Scheme 1.6).12 After cyclization of the amide 1.36, an oxazoline allowing for alkylation 
and subsequent reduction with NaBH3CN delivered threonine derivative 1.37.  Transient 
TMS silylation of 1.37 followed by acylation with acryloyl chloride and Dess-Martin 
oxidation provided keto amide 1.38.  Cyclization of 1.38 by an intramolecular Baylis-
Hillman reaction using quinuclidine led to a γ-lactam (dr 9:1) and subsequent silylation 
provided ether 1.39. Radical cyclization with tributyltin hydride delivered a bicyclic 
compound which was subjected to hydrogenolysis of the benzyl ether and oxidation to 
give aldehyde 1.40. An organozinc reagent was utilized to install the remaining two 
stereocenters in a highly diastereoselective fashion. After further manipulations, 
salinosporamide A (1.9) was obtained by saponification, β-lactone formation with 
BOPCl, and chlorination in 13% overall yield and a longest linear sequence of 17 steps.  
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Recently, our group reported the total synthesis of salinosporamide A and 
cinnabaramide A using the NCAL reaction as a key step (Scheme 1.7). Reductive 
amination of O-benzyl-L-serine 1.43 with p-anisaldehyde following the esterification 
provided (S)-N-PMB serine allyl ester 1.45. The PMB allyl ester 1.45 was coupled with 
hetero-ketene dimer 1.46, to provide keto acids 1.47a/b following Pd-mediated ester 
deprotection. The key bis-cyclization proceeded in 25-35% yield with a diastereomeric 
ratio of 2-3:1 for β-lactones 1.48 and 1.49, which favored that found in salinosporamide.  
Deprotection of the benzyl ether enabled enrichment of the major diastereomer 1.50 to 
6:1 upon purification. Modified Moffatt oxidation13 using 1-(1,3-dimethylaminopropyl)-
3-ethyl carbodiimide hydrochloride (EDCI) 14  and dichloroacetic acid 15  provided the 
corresponding aldehydes with a diastereomeric ratio of 14:1, which was carried forward 
directly to the next step. Applying the method developed by Corey for side chain 
attachment to the aldehyde using a zinc reagent generated in situ gave alcohols 1.51 in 
33% yield (2 steps, dr = 3.5:1).  Finally, deprotection of the PMB group provided rac-
salinosporamide A 1.9 diastereomerically pure in 49% yield. 
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Recently Liu reported the isolation of the fused β-lactone vibralactone 1.7 from 
cultures of the Basidiomycete Boreostereum vibrans. They assigned the structure by 
detailed spectroscopic analysis, and the absolute stereochemistry was assigned by 
computational methods.  
Vibratone covalently but reversibly modifies the active site serine of the enzyme via 
acylation by the β-lactone. The first total synthesis of vibratone was completed by Snide 
in 2007 (Scheme 1.8). 
The starting carboxylate was obtained from reductive alkylation of 2-
methoxybenzoate with prenyl bromide and further hydrolysis. The cyclopentenal spiro-
lactone 1.55 was delivered after a series of standard manipulations via several steps. 
Zinc mediated retro-iodolactonization delivered aldehyde 1.57 with moderate yield and 
subsequent intramolecular esterfication with TFA completed β-lactone 1.58. Finally 
reduction of the aldehyde 1.58 by NaBH4 delivered vibralactone 1.7 with 78% yield. 
 
13 
Scheme 1.8 
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B. Recently Isolated β-Lactone Containing Natural Products and Synthetic 
Derivatives 
Several β-lactone containing natural products have interesting biologically great 
activity such as Verbanaceae 1.60, Oxazolomycin1.63 and lajollamycin 1.62 have not 
synthesized yet (Figure 1.4).  
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Figure 1.4 Recently Isolated Natural Products Containing  
                    β-Lactone and Synthetic Derivatives 
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In 1998, ONeill reported Lantana camara L. (verbanaceae).  Lantana camara L. 
(verbanaceae), commonly known as wild sage, is a flowering shrub indigenous to 
tropical America and Africa. 16  Methanolic extract 1.60 prepared from the leaves of 
Lantana camara have been found to inhibit human thrombin.17 Analysis of the HRMS 
and 1D and 2D NMR data for extract led to the structure proposed. An X-ray crystal 
structure confirmed the proposed structure. 
Diterpene isovalerate ester, spongiolactone 1.61, was isolated from Spongionella 
gracilis as part of a targeted re-isolation of larger quantities of the gracilin family of 
compounds for screening in a variety in unspecified bioassays. Although spongiolactone 
1.61 possesses a heavily rearranged carbon skeleton, it is still thought to originate from a 
spongian diterpene.18 Neither a synthesis nor the biological activity has been reported for 
this compound.  
Over the past two decades a large number of complex bioactive natural products 
containing β-lactones and methylene-interrupted oxazolyl-triene motif have been 
isolated from strains of Streptomyces sp. Oxazolomycin A 1.63a,19 isolated in 1985, is 
the parent of this class of antibiotics, which also includes oxazolomycins B 1.63b and C 
1.63c,20  curromycins A 1.63e and B 1.63f,21 16-methyloxazolomycin 1.63d,22 and 
lajollamycin 1.62.23 These compounds are structurally novel antibiotic and antiviral 
agents, whose bioactivity has been proposed to arise from their protonophoric properties. 
There are no syntheses reported to the best of our knowledge, although there are a 
number of groups that have established strategies for the synthesis of core components, 
including the middle component,24 and the left-hand portion.25  
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 CHAPTER II 
TOTAL SYNTHESIS OF BELACTOSIN C AND DERIVATIVES* 
 
A. Isolation and Biological Activity of the Belactosins  
The recently isolated bacterial metabolites, belactosins A-C from a fermentation 
broth of Streptomyces sp. UCK14, uniquely contain a β-lactone dipeptide motif and 
exhibit anticancer activities26 that has been subsequently attributed to regulation of the 
ubiquitin-proteasome pathway through inhibition of the 20S proteasome (Figure 2.1).27 
The proteasome, an intracellular proteolytic system, shows the peptidase profile of 
chymotrypsin, trypsin, and peptidyglutamyl-peptide protease.28  Belactosins A and C 
possess the greatest inhibitory activity toward chymotrypsin of the rabbit 20S 
proteasome (IC50 = 0.21 µM), whereas when the β-lactone moiety is absent as in 
belactosin B there is greatly reduced activity (>10 µM). In addition, degradation studies 
of belactosin A suggested that the β-lactone moiety was indeed responsible for the 
observed antiproliferative activity.2  
                                                
* Reproduced in part from Cho, S. W.; Romo, D. Total Synthesis of Belactosin C and 
Congeners via the Tandem Mukaiyama Aldol-Lactonization Process, Org. Lett. 2007, 
9, 1537. Published work copyright 2007 American Chemical Society. 
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A benzyl ester derivative KF33955, which is presumably more cell permeable 
exhibited greater growth inhibitory activity toward HeLa S3 cells than both belactosins 
A and C (IC50 = 0.46 µM vs 51 and 200 µM, respectively). 
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Figure 2.1  Structure of Belactosin A and C and Other β-Lactones: Inhibitors of the          
Proteasome and Thioesterase Domain of Fatty Acid Synthase  
 
A recent X-ray study of N-CBz-O-Bn homobelactosin C bound to the yeast 20S 
proteasome revealed that the N-terminal γ-threonine residue in the catalytic pocket of the 
proteasome is acylated by the β-lactone moiety, and the orientation differs from 
omuralide a β-lactone-containing proteasome inhibitor (Figure 2.2).29 
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Figure 2.2 Surface Representation of the Chymotryptic-like Active Site in Complex 
with Omuralide (Left) and Homobelactosin C (Right), Covalently Bound to Thr-1 
(depicted in white). (Reproduced from ref.20) 
 
Proteasome inhibitors are also of high interest as research tools. Since the 
proteasome is a protein complex in eukaryotic cells that degrades certain proteins, 
inhibition of its activity can induce cell death in cancer cells or disrupt major cell 
signaling cascades. These compounds may also have potential usefulness for treatment 
of malaria, cancer, inflammation and infectious diseases. We have reported other β-
lactone containing compounds such as tetrahydrolipstatin (orlistat 1.5) and derivatives 
that act as inhibitors of the thioesterase domain of fatty acid synthase (FAS-TE), a 
reduced form of the natural product lipstatin is an antiobesity agent marketed under the 
tradename of Xenical that was recently approved by the FDA as the first over-the-
counter weight-loss medication (Figure 2.1). The mechanism of inhibition involves 
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covalent but reversible modification of the active site serine via acylation by the β-
lactone. Therefore Belactosin C may be a feasible inhibitor of the FAS-TE even though 
there is no currently reported activity.  
 
B. Previous Syntheses of Belactosins  
To date five total syntheses of belactosin A and C and their derivatives have been 
reported30 including ours along with several studies regarding fragment syntheses.31 
De Meijere has since reported progress toward belactosin C32 along with studies by 
Kumaraswamy reporting two different synthetic method for belactosin C and 
derivatives, whereas, Armstrong has reported the synthesis of the belactosin A33.  
In 2004,  De Meijere utilized a chiral BOX ligand 2.11 to make the β-lactone which 
required several steps to make (Scheme 2.1). 
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A (Z)-silylketene acetal was employed in the Mukaiyama-type aldol reaction with 
ethyl glyoxalate, using Sn(OTf)2/BOX as the catalytic system. This reaction gave a high 
enantioselectivty (99% ee) and diastereoselectivity (syn : anti> 40: 1). 
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Almost same time, Armstrong used a chiral oxazoline to install the chiral β-lactone 
(Scheme 1.2). The key chlorination step was prepared by prior conversion to the dianion 
using LiHMDS followed by treatment with carbon tetrachloride. Lactonization was 
achieved as described by Barlaam,34 and the excellent diastereoselectivity presumably 
came from a cyclic transition state presenting the less hindered site of the enolate to the 
chlorinating reagent.  
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The key chlorination step was prepared by prior conversion to the dianion using 
LiHMDS followed by treatment with carbon tetrachloride. Lactonization was achieved 
as described by Barlaam, and the excellent diastereoselectivity presumably came from a 
cyclic transition state presenting the less hindered site of the enolate to the chlorinating 
reagent.  
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More recently, Kumaraswamy has reported belactosin C synthesis using Oppolzers 
sultam directed aldol reaction as a key step (Scheme 2.3) 
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The Oppolzers sultam directed aldol reaction was achieved by using two equiv. 
TiCl4 and the anti isomer was obtained exclusively through an open transition state as 
proposed by Oppolzar. 
Kumaraswamy reported another synthesis of belactosin C using a proline catalyzed 
crossed-aldol reaction, which delivered the chirality from catalytic S-proline (Scheme 
2.4).35   
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Belactosins A and C possess a trans-β-lactone moiety as a key structural feature. 
Although new methods for the synthesis of β-lactones have drawn great interest in recent 
years due to their great versatility and utility in natural product synthesis,36  as we 
discussed here, relatively few methods exist for the synthesis of these compounds in 
optically pure form.37   We have developed diastereoselective and enantioselective 
methods for the preparation of β-lactones employing chiral Lewis-acid catalyzed [2+2] 
cycloadditions of ketenes and aldehydes, a tandem Mukaiyama aldol-lactonization 
(TMAL) process and a nucleophile catalyzed aldol lactonization (NCAL) of 
aldehydeacids.  In case of TMAL delivers trans β-lactones in one step sequence.  
 
C. The Tandem Mukaiyama Aldol-Lactonization (TMAL) Process  
The TMAL process builds on Hirai’s initial discovery38 where a single β-lactone, 4-
(p-nitrophenyl)-3-methyl oxetan-2-one 2.27 was prepared in 23% yield with high cis 
diasteroselectivity (Scheme 2.5).   
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 Scheme 2.5  
O2N
O
H N
OTBS
S
Me
Me
O2N
O
O
MeZnCl2 (1.0 equiv)
CH2Cl2, rt, 5h
23%
+
2.25 2.26 2.27  
 
During our investigation of the TMAL reaction we discovered a new TMAL process 
which provide trans β-lactones exclusively major diastereomer (Scheme 2.6).  
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In the course of optimization of various reaction parameters, several important were 
found. The thiopyridine moiety of ketene acetal was crucial to the success of this 
reaction. Second, ZnCl2 is the only Lewis acid to deliver trans-β-lactones in the TMAL 
process so far. Finally, the steric bulk of the silyl group of ketene acetal was found to 
play an important role in the outcome of the TMAL process. we found that less bulky 
silyl groups increase the yield of β-lactones as previously observed. Based on our 
observations, we proposed mechanism in the TMAL reactions (Scheme 2.7) 
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Our group and others39  have used this method to prepare various β-lactones 
including natural products such as (−)-panclicin D,40a,c tetrahydrolipstatin/orlistat,4a,41 (−)-
grandinolide,42 and okinonellin B,43 the latter two targets being accessed via β-lactone 
intermediates obtained by the TMAL process 
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D. Retrosynthetic Analysis of Belactosin C 
In general, the published syntheses of belactosins require multiple steps to construct 
the key β-lactone nucleus involving a late-stage lactonization step. We were attracted to 
the possibility of the direct construction of belactosin and derivatives via the TMAL 
process using a chiral silyl ketene acetal and the requisite glyoxamide dipeptide (strategy 
A, Figure 2.3). This strategy would enable rapid SAR studies of these enzyme inhibitors 
toward the proteasome and possibly other cellular proteins. Although this reaction would 
constitute a double diastereoselective process, a high degree of diastereoselectivity was 
not assured given the distance between stereogenic centers. Therefore, an alternative 
strategy would employ chiral glyoxamides11 bearing cleavable chiral auxiliaries to 
impart higher diastereoselectivity via double diastereodifferentiation due to the greater 
proximity of the resident stereogenic centers (strategy B, Figure 3). The resulting β-
lactone carboxylic acid 2.24 and simpler β-lactone acids could then be coupled to the 
protected orn-ala dipeptide and variations structure-activity studies. 
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A. Double Diastereoselective (Distal) : Ketene Acetal-Based 
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B. Double Diastereoselective (Proximal) : Glyoxal-Chiral Auxiliary-Based 
O
O
H
N
O
N
H
H2N
CO2HO
H H
O
O
O
HO
H H
TMAL
+
Reagent Control
TMAL
SPy
OTES
+XcO
O
O
NH2N
H
CbzHN
CO2BnO
Peptide
Coupling
Amide
Coupling 2.42 2.24
2.43 2.41  
Figure 2.3 Retrosyntheses of Belactosin C Employing Double Diastereoselection 
 
E. Synthesis of Peptide & Ketene Acetal Fragment  
The synthesis of the required chiral silyl ketene acetal 2.41 commenced with the 
known hydrodeamination44 of L-isoleucine 2.44 with hydroxylamine-O-sulfonic acid 
followed by conversion to thioester 46a via the acid chloride (Scheme 2.8).45 Conversion 
to the silyl ketene acetal (E/Z, ~9:1) was accomplished using procedures described 
previously.5 An identical route was employed to prepare the achiral silyl ketene acetal 
2.41b. 
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After ketene acetal 2.41a/b in hand, we started the peptitide fragment synthesis from 
the Cbz-alanine 2.48 (Scheme 2.9). EDCI coupling with Cbz-alanine 2.48 and Fmoc-
ornithine 2.49 delivered dipeptide 2.50 in moderate yield. However, Fmoc deprotection 
conditions with various bases and solvents did not give the desired free amine 2.51 but 
the cyclic amide 2.52. 
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To prevent intramolecular cyclization, we tried in-situ capturing with acyloyl 
chloride but we did not get any success (Scheme 2.10). 
Scheme 2.10 
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Therefore we need to change the protection groups with Boc to change this 
deprotection step. Benzylation of the diprotected ornithine 2.52 with Cbz-Cl gave the 
benzyl ester 2.53, which, after removal of the Fmoc group with Et2NH, was coupled 
with Cbz-Ala-OH (Scheme 2.11). Acylation with acryloyl chloride provided amide 2.40 
which was converted via ozonolysis to a mixture of the desired glyoxamide 2.56 and its 
corresponding hydrate mixture after purification by flash column chromatography. 
Stirring the mixture with 4 Å molecular sieves enabled dehydration to deliver the desired 
glyoxamide 2.56 and checked by H-NMR. Glyoxamide 1 which was treated after 24 h 
stirring 4 Å molecular sieves in CH2Cl2 was suitable for the subsequent TMAL process.  
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F. Synthesis of the β-Lactone  
1. Synthesis Using a Double Diastereoselective (Distal) TMAL 
With chiral and achiral ketene acetals 2.41a/b and glyoxamide dipeptide 2.57 in 
hand, we set out to study the inherent diastereoselectivity, if any, imparted by the 
dipeptide on the configuration of the β-lactone generated. On the basis of previous 
studies of the ZnCl2-mediated TMAL process, we expected exclusive formation of trans-
β-lactone. Indeed, treatment of aldehyde 2.56 with ketene acetal 2.41b under standard 
TMAL conditions gave exclusively trans-β-lactones 2.57-1a/b albeit in low yield. On 
the basis of 13C NMR, the ratio of diastereomers 2.57-1a/b was ~1:1 (Scheme 2.12). As 
expected, the stereogenic centers of the dipeptide are too distal to impart any inherent 
bias on the diastereoselectivity.  
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However when chiral ketene acetal 2.41a was employed, this led to the formation of 
four diastereomers including cis-β-lactones with a slight preference for trans-
diastereomers (Scheme 2.13). In this case, the stereogenic center of the ketene acetal 
clearly does impact the diastereoselectivity but not in a favorable manner. After careful 
purification, the cis-(2.58a/2.58b) and trans-(2.58c/2.58d) diastereomers could be 
separated; however, the two trans-diastereomers were inseparable.  
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The trans diastereomers were deprotected by hydrogenolysis with H2/Pd with 
retention of the 1.5:2 ratios of diastereomers which was not more separable (Scheme 
2.14). 
 
Scheme 2.14 
 
O
O
H
N
O
N
H
CbzHN
CO2BnO
H H
H2, Pd/C
THF/HCO2H
O
O
H
N
O
N
H
H2N
CO2HO
H H
+ 2.58d
+ trans-diastereomer1.5:2
(92%)2.58c
 
32 
Alternative reaction conditions were explored in order to increase the 
diastereoselectivity (Table 2.1). Most solvents did not give the desired β-lactones except 
THF. The TMAL reaction in THF had not reported, but it proceeded in this reaction. 
Although, we could obtain exclusively the desired trans- β-lactone diastereomers, the 
yield was below 1%. THF gave the desired trans-β-lactones while also increasing the 
ratio of desired trans-β-lactone diastereomers from 1.2: 1 to 3:1. 
 
Table 2.1 TMAL Reaction with Various Solvents 
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solvent cis:trans yield (%) 
CH2Cl2 2 : 3.5 30 
CH3CN 0 0 
Toluene 0 No reaction 
THF 0 : 100 Trace 
 
The ratio (3:1) of the products matched the E/Z ratio (3:1) of the ketene acetal 
(Scheme 2.15). Therefore, we decided to examine the relationship between the 
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diastereomeric ratio of the product of TMAL reaction and the E/Z ratio of ketene acetal. 
Indeed, with exclusively E-ketene acetal (17:1) we obtained the desired protected 
belactosin C in a ratio of 8:1 implying that the Eketene acetal led to the desired 
diastereomer. However, the yield of this TMAL reaction was poor, which necessitated 
the use of alternate reaction conditions. 
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2. Synthesis Using a Double Diastereoselective (Proximal) TMAL  
We next studied the TMAL reactions of glyoxylate esters including those bearing a 
chiral auxiliary, which could be readily deprotected and then coupled to a number of 
dipeptides. Carefully examination of the chiral auxiliary candidates required easy 
approachable synthesis and deprotection by hydrogenolysis, due to the somewhat labile 
β-lactone moiety that would be present.46  
For model study of incorporating the desired functionality, benzylglyoxylate was 
prepared using same reaction sequence from benzyl alcohol and the TMAL reaction. The 
benzyl group was deprotected by H2/Pd and to give β-lactone acid, which was 
subsequently coupled with dipeptide to give the products (Scheme 2.16). 
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We then selected a few chiral auxiliary candidates and initiated the synthesis. (R)-
phenethyl alcohol was selected as a chiral auxiliary since it can be obtained easily and 
efficiently. However, this auxiliary did not give any significant increase in the 
diastereoselectivity and just gave 4 diastereomers (Scheme 2.17). 
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Lately, we examined the possibility of chiral ephedrine derivatives as auxiliaries. 
We expected the coordination of Zn, N- and O- and these rigid conformations would fix 
the transition state arrangement, which would lead to high diastereoselectivity  
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Based on this assumption, we began the synthesis of new auxiliary from ephedrine. 
N-methylation was achieved by formylation and subsequent treatment with acryloyl 
chloride to give acrylate 2.67. Oxidative cleavage of acrylate 2.67 was expected to give 
the glyoxylate. However, only ketone 2.68 was observed (Scheme 2.18), presumably 
arised from the oxidation of the amine to the N-oxide with intramolecular elimination.  
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To avoid the formation of ketone 2.68, the amine was protected with Boc to obtain 
the desired glyoxylate 2.71 in 92% yield. The TMAL reaction failed with glyoxylate 
2.71 since the Boc protecting group was unstable in the reaction conditions (Scheme 
2.19). 
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Therefore, other auxiliaries were used for the asymmetric TMAL reaction protocol. 
Finally, we elected to study a variant of the known tartrate-derived auxiliaries that would 
fit our criteria and also possessing C-2 symmetry. The synthesis commenced with known 
diol 2.74, available in four steps from (−)-L-dimethyl tartrate.47 Monoprotection of diol 
2.74 proceeded efficiently, and subsequent acylation with acryloyl chloride and 
oxidative cleavage of the double bond provided chiral glyoxylate 2.76 (Scheme 2.20). 
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Application of the TMAL process with chiral glyoxylate 2.76 delivered an 
equimolar mixture of cis- and trans-β-lactones in 73% yield; however, greater selectivity 
for one trans-diastereomer was obtained (2.77a/2.77b = 1:5, Scheme 2.22). Furthermore, 
the purification was greatly simplified in the presence of the chiral auxiliary enabling 
separation of the trans-diastereomers by simple column chromatography. 
From the purified cis-diastereomers, X-ray crystal structure analysis was obtained as 
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shown in Figure 2.4. 
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Figure 2.4. X-ray Crystal Structure of cis-β-Lactone Diastereomer 2.77 (some hydrogen 
atoms omitted for clarity) 
 
To determine if this was the matched or mismatched case for the required trans-
diastereomer, the enantiomeric glyoxylate ester ent-2.76 was prepared (Scheme 2.21) 
and utilized in the TMAL reaction. 
 However, this was the mismatched case as the diastereoselectivity of 2.78-1 a/b 
decreased to 1.5:1.  
Other derivatives were prepared with this method in order to test their bioactivities 
(Scheme2.21).  
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However, with many different ketene acetals, high diastereoselectivity could not be 
achieved in resulting inseparable mixtures (Scheme 2.22).  
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Cleavage of the chiral auxiliary by hydrogenolysis of ester 15a gave β-lactone acid 
(-)-3, which could be correlated to the same compound reported by Kumaraswamy ([ ]D 
-3.1; lit. ([ ]D -3.0).
34 Subsequent coupling with protected dipeptide 7 generated protected 
belactosin C 10c, and deprotection by the method of Armstrong33 gave belactosin C in 
diastereomerically pure form with the spectral data correlated well with those previously 
reported (Scheme 2.23).34  
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G. Dual Inhibitors of the Proteasome and Fatty Acid Synthase 
Inhibition of the enzymatic activity for both the proteasome and fatty acid synthase 
were saved for several belactosin derivatives by our collaborators at the Burnham 
Medical Research Institute in La Jolla, CA (Prof. Jeff Smith, Robyn Richardson). 
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2.57-1 2.57 2.57-2 2.58c/d belactosin
-c/d
Inhibition of the 20S Proteasome by Novel Belactosin Derivatives. 
Figure 2.5 Novel Belactosin Derivatives Inhibit the Turnover of a Fluorogenic Substrate 
by the 20S Proteasome 
 
The 20S proteasome (5 nM) was incubated with (A) 1.25 µM or (B) 50 µM test 
compound and 100 µM suc-LLVY-AMC substrate.  Fluorescence measurements were 
taken every ten minutes at 380/460 nm.  Results shown are the average of (A) triplicate 
or (B) duplicate data points. 
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Table 2.2 Inhibition of the Fatty Acid Synthase Thioesterase Domain by Belactosin C 
and Derivatives 
entry Belactosin derivatives FASTE IC50 (µM) 95% CI (µM) 
1 
O
O
H
N
O
N
H
CbzHN
CO2BnO
H H  
(1.3:1 dr) 
0.17 0.13 - 0.21 
2 
O
O
H
N
O
N
H
H2N
CO2HO
H H  
(1.3:1 dr) 
26.55 20.48 - 34.42 
3 
O
O
H
N
O
N
H
CbzHN
CO2BnO
H H  
(1:1 dr) 
3.98 3.35 - 4.61 
4 
O
O
H
N
O
N
H
CbzHN
CO2BnO
H H  
(1:1 dr) 
2.86 1.11 - 4.60 
5 
O
O
H
N
O
N
H
CbzHN
CO2BnO
H H  
(1:1 dr) 
0.16 0.13 - 0.19 
 
Novel belactosin derivatives inhibit the turnover of a fluorogenic substrate by fatty 
acid synthase thioesterase. The thioesterase (230 nM) was incubated with a range of test 
compound concentrations (100 µM to 0.16 µM) and 120 µM 4-MU-heptanoate 
substrate.  Fluorescence measurements were taken every five minutes at 350/450 nm.  
43 
Results shown are the calculated IC50 value and corresponding 95% confidence intervals 
from a dose-response curve fit of the data in triplicate. 
 
H. Conclusion 
The enantioselective synthesis of (-)-belactosin C and derivatives was accomplished 
in a concise manner employing the tandem, Mukaiyama aldol-lactonizaton (TMAL) 
process and test their bioactivities. One approach involved a distal double 
diastereoselective TMAL reaction with a dipeptide glyoxamide, whereas a second 
approach involved amide coupling of a dipeptide with a β-lactone carboxylic acid, 
obtained via the TMAL process employing a chiral silyl ketene acetal. Notable 
improvements in diastereoselectivity were achieved in a proximal double 
diastereoselective TMAL process. Enzymatic assays showed that the belactosins act as 
the dual inhibitors of the proteasome and the thioesterase domain of fatty acid synthase. 
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CHAPTER III 
SYNTHETIC STUDIES TOWARD SPONGIOLACTONE 
 
A. Isolation and Background  
Spongiolactone 3.2 which contains a cyclopentyl-fused β-lactone was isolated in 
1986 from Spongionellagracilis (Figure 3.1). The name spongio reflects the origin of the 
early examples of this class of diterpene in the dictyoceratid sponge genus Spongia.48 
The term spongian diterpene was first coined by Murphy and co-workers in 1979.1 In 
tandem with the ongoing discovery of a plethora of related metabolites possessing the 
same basic spongian diterpene skeleton 3.1, a wide variety of biological activities 
associated with this group of compounds have been reported. 49   The diterpene 
isovalerate ester, spongiolactone 3.2, was isolated from Spongionella gracilis as part of a 
targeted re-isolation of large quantities of the gracilin family of compounds for screening 
in a variety of bioassays. Although 3.2 possesses a heavily rearranged carbon skeleton, it 
clearly originates from related biosynthetic pathway leading to spongian diterpenes.50 
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Figure 3.1 Structure of Spongian Diterpene Skeleton, Spongiolactone,  
and a Known Simple Bizcyclic-β-Lactone 
 
Spongiolactone 3.2 was isolated as an optically active colorless oil ([α]D +67.6, 
C=1.7, CHCl3), and the IR spectrum showed two carbonyl absorptions at 1830 cm-1, 
typical of a β-lactone, and 1730 cm-1 attributed to an ester. 
Additional evidence for the structure was furnished by LAH reduction of 3.2 
followed by acetylation which afforded the expected triacetate 3.2ab, whose structure 
was assigned on consideration of its spectral data, ([α]D -10.3, C=0.4, CHCl3). 
No biological activity has been reported for this compound; however, the acylating 
potential of the resident β-lactone warrants screening for potential bioactivity. 
Comparison of a related, simpler bicyclic β-lactone with 1H-NMR data reported for the 
natural product verifies assignment of this region of the natural product. 
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B. The Nucleophile-Catalyzed Aldol Lactonization (NCAL) Reaction 
New methods for the synthesis of β-lactones have drawn great interest in recent 
years because of the great versatility and utility exhibited by these strained heterocycles 
in natural product synthesis.51  However, relatively few methods exist for the synthesis 
of these compounds in optically pure form.52Our group has developed diastereoselective 
and enantioselective methods for the preparation of β-lactones employing chiral Lewis-
acid catalyzed [2+2] cycloadditions of ketenes and aldehydes, a tandem Mukaiyama 
aldol-lactonization (TMAL) process and an intramolecular nucleophile catalyzed aldol 
lactonization (NCAL) employing both aldehydes and ketoacids.  The NCAL reaction is 
based on a several report by Wynberg for the enantioselective synthesis of β-lactones 
using cinchona alkaloid catalysts.53  
Wynberg found that cinchona alkaloids afforded excellent asymmetric induction in 
an intramolecular NCAL reaction (Scheme 3.1).54 The drawback of this initial method is 
the requirement of a ketene generator and the necessity of at least two chlorine 
substituents on the carbon adjacent to the carbonyl in ketone and aldehyde substrates 3.3. 
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The mechanism for this reaction was proposed by Wynberg (Scheme 3.2). Initial 
attack of ketene 3.4 by the chiral amine 3.6/3.7 forms the neutral ammonium enolate 
intermediate 3.8.   
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After enolate formation, the resulting enolate 3.8 undergoes an aldol reaction with 
aldehyde 3.3 to form aldolate 3.7, followed by cyclization to form oxetane 3.10.  Finally, 
elimination gives the final chiral β-lactone 3.5, thus regenerating the catalyst. A possible 
reason why this method works only with highly activated aldehydes is that the 
ammonium enolate intermediate 3.8 is not reactive enough to carry out the methodology 
reaction with unactivated aldehydes.  
Wynbergs work helped pioneer further explorations in this. Our group later 
reported that in situ generated ketene from acetyl chloride and Hunigs base delivered 
similar yields and selectivities compared to Wynbergs method, which was performed 
with a ketene generator.55 However, highly electrophilic carbonyl compounds remained 
a prerequisite for the formation of β-lactones (Scheme 3.3).  
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After an aggressive effort overcome limitations of the activated aldehydes, our 
group finally found that unactivated, non-α-chlorinated, aliphatic aldehydes participated 
as electrophiles in the NCAL reaction when it was run in an intramolecular fashion 
(Scheme 3.4).56 Mukaiyamas reagent, effectively activated the aldehyde acid substrates 
3.14  in-situ. 
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Scheme 3.4 
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The primary mechanistic pathway for this process with aldehyde acid substrates 
enabled an asymmetric organocatalyzed variant via an ammonium enolate 3.18, which is 
not possible via a [2+2] cycloaddition pathway (Scheme 3.5). A few years later, we 
expanded the reaction scope to induce ketone substrates 3.14 (R2 = alkyl). The 
nucleophile-promoted process reaction was facile and proceeded at ambient temperature. 
The extension to keto-acid substrates significantly expanded the scope of this process 
allowing access to bicyclic and tricyclic systems bearing masked tertiary alcohols and a 
reactive β-lactone moiety.57 
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Building on Wynbergs proposed mechanism, our group suggested that the activated 
acid 3.16 reacts with the cinchona alkaloid catalyst to produce an acyl ammonium 3.17, 
which is cab be deprotonated to form ammonium enolate 3.18. Intramolecular aldol 
lactonization of the ammonium enolate 3.18 furnishes β-lactone 3.20 with the recovery 
of the catalyst.  
 
C. Retrosynthetic Analysis  
The strategy to be employed for the β-lactone toward spogiolactone will involve 
application of the NCAL process as one of the final steps in the synthesis (Figure 3.2). 
Importantly, this application will allow us to investigate the possibility of double 
asymmetric synthesis in a more complex setting. Thus, the relative stereochemistry 
obtained with Et3N, O-AcQD, and O-AcQN as nucleophilic catalysts will be compared. 
The key intermediate aldehyde acid 3.23 can be obtained from TBS enol ether 3.24 by 
oxidative cleavage. TBS enol ether 3.24 will be prepared from triflate 3.26 through the 
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Heck coupling and finally, the decaline system of triflate 3.26 will be constructed from 1, 
3-cyclohexadienone 3.28 via several steps. 
 
O
OR
O
Spongiolactone 2
R=C(O)CH2CH(CH3)2
intramolecular
NCAL
CHO
OR
CO2H
Oxidative
Cleavage
OTIPS
OTIPS
Heck
Coupling
OTIPS
OTIPS
TfO+
OTIPS
OTIPS
S
S
H
R
R=SPh
Hajos-Parrish
Robinson
Annulation
OO
R
+
O
3.25 3.27
H
H
3.23 3.24
3.26
3.28 3.29  
Figure 3.2 Retrosynthetic Analysis of Spongiolactone 
 
 
D. Synthesis of the α -Substituted Cyclohexenone Core 
1. The Hajos-Parrish Procedure 
Synthesis of the decalin system 3.27 began with the application of the Hajos-Parrish 
procedure. 58  In order to install the thiophenyl group on the central carbon (C2), 
thiophenylchloride 3.31 was prepared with diphenyldithian 3.30 and thionyl chloride in 
quantitative yield. The thiophenylchloride 3.31 was used after evaporating solvent and 
remained thionyl chloride without further purification. The thiophenyl group was 
installed in the presence of sodium hydride and thiophenylchloride 3.31 to provide 3.33 
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in moderate yield.  The thiophenyl substituent was utilized to serve two purposes. 1) to 
give good stereoselectivity since the Hajos-Parrish procedure generally needs an alkyl 
group on the central carbon (C2) so the thiophenyl group was installed as a replacement 
(Scheme 3.6). 2) Also, the thiophenyl group, and it provides steric bulk useful in later 
steps can be easily removed. 
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Following the Hajos-Parrish procedure, methyl vinyl ketone was used to get 
triketone with Et3N as a base. The decaline alcohol 3.36 when the cyclization was 
carried out with (-)-proline. Either spongiolactone would be prepared using (L)-proline 
or (D)-proline. Since the absolute configuration of spongiolactone remains unknown.. 
Dehydration occurred with catalytic TsOH at reflux to give 3.36 with quantitative yield. 
The decaline 3.37  matched with reported results and showed good enantiomericpurity.48 
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After the successful decaline 3.36 synthesis, we began elaboration with ketone 
protection using ethylene glycol and tosic acid (Scheme 3.8). Although ketone protection 
is usually usual reaction to chemist, this was detrimental to this substrate 3.36. A variety 
of reaction conditions such as TsOH/Dean-Stark, TsOH/Molecular-Sieve, H2SO4, 
Ethylene glycol TMS ether/TMSOTf were screened and all led to decomposition of the 
sulfur moiety. 
Scheme 3.8 
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Faced with these difficulties, the protecting group was changed to TMSCl 
(Scheme 3.9). Milder reaction conditions may give compound 3.38 without 
decomposition. However, with various bases the phenyl sulfuryl group was easily  
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decomposed. 
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Although the Hajos-Parrish procedure is an most interesting challenge, due to the 
difficulties encountered in the mono protection of the ketone, this route was eventually 
abandoned and to pursue a more feasible strategy  to construct first key intermediate 
 
2. Michael Addition/Enolate Trapping Strategy 
After considering several strategies, a Michael addition/ enolate trappings strategy 
was pursued. Michael addition of vinyl cuprate to the cyclohexenone 3.41 and 
subsequent enolate trapping with an electrophile such as triflate could afford our key 
intermediate 3.40. The triflate would then be used in a Heck reaction to provide coupling 
adduct. 
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Figure 3.3 Michael Addition/Enolate Trapping Strategy 
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The ethyl ester 3.41 can be prepared from cyclohexenone 3.42 by the Baylis-
Hillman reaction. Finally, the cyclohexenone 3.42 will be constructed from 3-butyne-2-
ol  via several steps. 
The Diels-Alder reaction also continues to play a crucial role in the synthesis of 
complex molecules. 59  Rawal reported a racemic and asymmetric substituted 
cyclohexenone 3.48 synthesis using the Diels-Alder reaction with achiral and chiral 1-
(2-oxazolidinon-3yl)-3-siloxy-1,3-butadienes. 60   Although Rawals protocol reported 
chiral cyclohexenone 3.48, we decided to begin the full synthetic route from racemic 
cyclohexenone 3.48 toward spongiolactone and then complete the asymmetric synthesis 
later. 
 Racemic cyclohexenone 3.48 was prepared by Rawal’s protocol without any 
problem on milligram scale (Scheme 3.10). However, we were quickly disappointed as 
we attempted scale-up of the Diels-Alder reaction giving only minimal amounts of the 
desired product 3.46. Unfortunately, it required much effort to find optimal scale up 
conditions without success. The maximum reaction conditions for the Diels-Alder 
reaction in our lab was 3g scale. The exact problem encountered upon  scale-up remains 
elusive. 
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Even though the scale-up was a problem, the desired cyclohexenone 3.48 was in 
hand. Therefore, the α-alkylation of α,β-unsaturated ketones 3.48, an important 
transformation in our synthesis, was explored with the Bayliss-Hillman process.61 While 
various methods for the α-functionalization of α,β-unsaturated enones have been 
developed using a stepwise approach, a direct method for facile introduction of an alkyl 
group was required rather harsh conditions; sealed tube at 185oC in DMF or 1,3-
dimethyl-2-imidazolidinone (DMEU) as reported by Hwu (Scheme 3.11).62   
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Even with the high temperatures, the reaction pathway was still attractive. Therefore 
we attempted to utilize Hwus method to install α-alkyl group without success.  The 
strict high temperature requirements of the α-alkylation in DMEU led complex 
molecules to decompose and not obtain any of the α-alkylation product. Instead a 
complex mixture of desilanolated compound resulted.  
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Based on Hwus experiment and suggested mechanism, we assumed that the high 
temperature accelerated elimination of the silanoxide after double enolate formation 
leading to dienone 3.52 (Scheme 3.12). 
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Therefore we re-examined Hwus conditions carefully as we required mild 
temperatures. Milder conditions for direct α-alkylation has been developed and were 
tested in our group. Many combinations of bases and solvents were tested at room 
temperature (Table 3.1)  
Table 3.1 α-Alkylation Reaction Conditions 
O
+ CO2Me
base
23oC, solvent
24h
O
CO2Me
3.49 3.50 3.51  
entry solvent base yield 
1 DMF DBU 1% < 
2 DMF DMAP 0 
3 MeOH NaOMe Trace 
4 THF DBU 0 
5 THF DABCO 0 
6 CH3CN DBU 80% 
7 Toluene DBU 0 
 
Most conditions did not provide the desired outcome; however, use of acetonitrile 
gave the desired product at room temperatre. Hwu reported 55% yield in acetonitrile 
with DBU(0.2 equiv.) at 185 oC. Unexpectedly, α-alkylation conducted in acetonitrile 
with DBU (1.0 equiv.) at room temperature afforded the α-alkylation product in 80% 
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yield. We then tried the α-alkylation of our key intermediate 3.53 (Scheme 3.13) and 
were able to obtain the desired product 3.53 on small scale (10 mg).  However, the same 
by-product 3.52 was obtained on large scale. Further optimization of there reaction 
condition are required to use this protocol in our synthesis. However, this protocol is 
useful to construct α-alkylation of various enones. 
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After the minor success of the •α-alkylation reaction, our goal was to find 
conditions for cuprate addition and enolate capture with the triflate. Model studies were 
conducted to evaluate various reaction methods. Most cases intra-molecular cyclization 
was occurred to delivered cyclic ester after Michael addition (Scheme 3.14).  
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For the problem at hand in model compound and α,β-unsaturated ketones 3.53 
formation, it came to our attention that another α,β-unsaturated ketones with bulkier 
ester would solve the problem. 
4-Hydroxymethyl cyclohex-2-enone 3.47 was investigated (Scheme 3.15). As 
expected the base deprotonated the hydroxyl proton and the resulting oxygen anion was 
not a good leaving group. decomposition reaction would be prevented based on our 
suggested mechanism. Reaction conditions for including Hwus method were explored 
without success. In most reactions, the same decomposition product 3.51 was obtained. 
 
Scheme 3.15 
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Alternatively, 4-Methyloxylcarbonyl cyclohex-2-enone 3.56 was selected to prevent 
side reactions (Figure 3.4). Even if proton abstraction of C-1 occurs, the intermediate 
should be stable, this preventing the side reaction from occurring. 
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Figure 3.4. α-Alkylation Reaction with Methyl ester 
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Based on this hypothesis, we started to make 4-methyloxylcabonyl cylclohex-2-
enone 3.56 from intermediate 3.46 (Scheme 3.16). However, TBS deprotection with 
HF/pyridine delivered only cyclohexanone 3.58 through this route. The poor leaving 
group ability of the methyl ester 3.46 at least partially stems from lack of the hydrogen 
bonding comparing to the previous reaction with the hydroxyl group, implying that a 
leaving group with hydrogen bonding character is required. 
After many attempts to make cyclohexenone 3.59 invariably failed, we pursued an 
alternate route.  
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We finally succeeded in making cyclohexenone 3.59 via 4steps (Scheme 3.17).  
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Not surprisingly, cyclohexenone 3.59 was obtained along with olefin isomer 3.65. 
The α-alkylation reaction was tried since this substrate offered the same transition state 
after proton abstraction. Indeed, the reaction worked without decomposition. However, 
the product was not α-alkylated but γ-alkylated (Scheme 3.18). 
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Although the C-3 position has electronically the more charge density than the C-1 
position, only C-1 alkylated product 3.66 was obtained. DBU-H+ could be blocking the 
ketone at the C-3 position. Therefore various bases such as LiHMDS, NaHMDS, 
KHMDS, NaH, LDA and LDA/HMPA were screened and all led to mixture of γ-
alkylation 3.66a and α,γ-dialkylated products 3.66b. Although alkylation of Hagemanns 
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ester (ethyl 2-methyl-4-oxocyclohex-2-enecarboxylate) has been reported 5:5 ratio of 
products at C-3: C-1, the desired product was not obtained (Table 3.2). 
 
Table 3.2 Approached α-Alkylation 
base/THF
t-butyl acylate
O
MeO2C
+
CO2
tBu
O
MeO2C
CO2tBu
tBuO2C
3.66a 3.66b
O
CO2Me
O
CO2Me
+
ratio = 1:2
3.59 3.65
 
entry base products (3.66a:3.66b) 
1 LiHMDS 10:1 
2 NaHMDS 8:2 
3 KHMDS 8:2 
4 NaH 8:2 
5 LDA 100:0 
6 LDA/HMPA 100:0 
 
Although the α-alkylation route is more concise route, this route was eventually 
modified as we sought for a more productive strategy.  
Michael addition to α,β-unsaturated ketone, electophile capturing is a well known 
strategy (Scheme 3.19). Though formation of a thermodynamically controlled enolate 
would not be entirely selective, each triflate could be separable upon further reaction. 
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Scheme 3.19 
O O
OR
O
TBSO OTBS
1) michael addition
2) α-alkylation
themodynamic
enolate
Trilate
OTf
OR
O
OTBS
3.48 3.67 3.68  
Based on the revised strategy, Michael addition and acrylate capturing was tried 
with various reaction conditions without success (Scheme 3.20). Most reactions was  
stopped after Michael addition using vinyl cuprate. Therefore we attempted the sequence 
in a stepwise fashion. 
 
Scheme 3.20  
1. CuI,
2.t-butyl acrylate
O O
HMPA
OtBu
O
MgBr
TBSO OTBS
3.48 3.67  
 
First, the TMS enol ether 3.68 was synthesized by Michael addition followed by 
TMS capture with TMSCl/HMPA (Scheme 3.21). In-situ TMS deprotection using MeLi 
with acrylate did not furnish.  Usually, electrophile of this reaction type is aldehydes or 
alky halides. 
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Scheme 3.21 
2.t-butyl acrylate
O
OtBu
O
OTBS
3.67
1. CuI,
2.TMSCl
O OTMS
HMPA
MgBr
TBSO OTBS
1. MeLi, THF
HMPA
3.48 3.68  
 
 Therefore alkyl bromide was used but it led only to decomposition. In order to 
increase the electrophilicity of the acrylate, metal reagents were used in conjunction. 
Nonetheless, some examples were known with methyl acrylate, our reaction did not 
work with either SnCl4 or TiCl4 giving only the desilated compound 3.69. The known 
reaction have less hindrance at the β−position, which is presumably the underlying cause 
for the ineffectiveness in our system. Since t-butyl ester did not led to a productive 
pathway, alternative pathway were pursued. 
 
Scheme 3.22 
cat, DCM
t-butyl acrylate
OTMS O
TBSO OH
cat : SnCl4, TiCl4
3.68 3.69  
 
 After careful consideration, the Dahn-Hauser protocol may be useful in preparing 
the key intermediate 3.72 (Scheme 3.23). This protocol would deliver the racemic 
synthesis for spongiolactone. After completion of racemic synthesis, we will move 
forward to asymmetric synthesis. 
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3. Stork/Danheiser Strategy 
Based on the Stock-Danheiser protocol, the synthesis of t-butyl ester 3.72 was 
planned (Scheme 3.23). 
 
Scheme 3.23 
O O MeO O
CO2tBu
O
RO
CO2tBu
3.70 3.71 3.72  
 
Although many alkyl group installation methods were reported, t-butyl acrylate was 
unknown to the best of our knowledge. Low activity of t-butyl acrylate may be the 
reason. After careful optimization K2CO3 as a base in DMF/reflux delivered the desired 
t-butyl ester 3.73 in moderate yield.  
 
Scheme 3.24 
O O O O
CO2tBu
DMF
K2CO3
t-butyl acrylate
3.70 3.73  
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The ketone in t-butyl ester 3.74 was then methylated after enol formation in the 
presence of dimethyl sulfate and K2CO3, which gave methyl enolate 3.71. The reaction 
was accomplished in quantitative yield. 
 
3.73 3.71
O O
CO2tBu
MeO O
CO2tBu
dimethylsulfate
K2CO3
Acetone
 
 
Finally the α-hydroxymethyl group was needed to construct key intermediate. 
Therefore methyl ester was selected and reaction conditions were carefully investigated 
(Table 3.3). In case of chloromethylester as a electrophile, anhydride formation was the 
major, where the cyanomethylester delivered the desired product 3.74a exclusively.  
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Table 3.3 Methyl Ester Formation 
MeO O
CO2tBu
MeO O
CO2tBu
O
OMe
base
THF
3.74a
electrophile
MeO O
CO2tBu
O
OMe
3.74b
CO2Me MeO O
CO2tBu
CO2Me
3.74c
3.71
 
 
entry electrophile base products  
1 ClCO2Me LiHMDS 2c 
2 ClCO2Me LiHMDS/HMPA 2b + 2c 
3 ClCO2Me LDA 2c 
4 ClCO2Me LDA/HMPA 2b + 2c 
5 CNCO2Me LDA 2b + 2c 
6 CNCO2Me LDA/HMPA 2a 
 
 
With the desired methyl ester 3.74a in hand, reduction with 3equiv. DIBAL in THF 
was tried (Scheme 3.25). Upon comparison of the reactivity and steric effect of three 
carbonyl groups, we expect the reduction of only the methyl ester and ketone. 
Unfortunately many adducts were produced and none of the desired compound was 
obtained. 
 
Scheme 3.25 
MeO
O
O O
THF
DIBAL
O
O
MeO
O
O OH
OH
3.74a 3.75  
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The messy reaction is most likely due to the tautomerization of starting α-keto ester 
(Scheme 3.26). This effectivity reduced similar the reactivity of the 3.74 as a 
electrophile when DIBAL was attached providing electrophilicities of each of the 
carbonyl functionalities present. 
 
Scheme 3.26 
3.74a 3.74d
MeO O
CO2tBu
O
OMe
MeO OH
CO2tBu
O
OMe
 
 
An in situ hydroxyl methyl installation method was discovered after many trials 
with the benzyloxy chloromethyl ether (Scheme 3.27). Indeed benzyloxy chloromethyl 
ether gave the desired hydroxyl methyl group in-situ in the benzyl protected form. 
 
Scheme 3.27 
MeO O
CO2tBu
MeO O
CO2tBu
OBn
LDA
THF
BnOCH2Cl
42%
-42oC3.73 3.76
 
 
Although the desired compound was provided, the yield needed improvement. The 
yield was increased to 78% by changing the reaction temperature (Table 3.4). The key 
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parameter in this reaction was reaction temperature, -20 oC-25 oC in order to have good 
productivity. When the temperature dropped below -25 oC or raised above  -20 oC the 
yield was significantly suffered giving half the product. 
 
Table 3.4 Benzyl Ether Formation Conditions 
MeO O
CO2tBu
MeO O
CO2tBu
OBn
LDA
THF
BnOCH2Cl
3.73 3.76  
entry temperature (°C) yield (%) 
1 -78 0 
2 -43 43 
3 -20 78 
4 0 31 
 
After successful optimization of the reaction, we moved forward to the key 
synthetic intermediate. The reduction of ketone 3.76 with DIBAL and acid hydrolysis of 
the reduced compound 3.77a with aqueous HCl delivered our desired key intermediate 
3.78 was obtained (Scheme 3.28). DIBAL reduction condition, we obtained 70% desired 
product 3.77a as 3:1 ratio of cis:trans and 30% 1,4-addition product 3.77b, which may 
be due to the steric hindrance of starting enone. 
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Scheme 3.28 
MeO O
CO2tBu
OBn
DIBAL
70%
THF
MeO OH
CO2tBu
OBn
+
O
CO2tBu
OBn
HCl
THF
O
CO2tBu
OBn
MeO OH
CO2tBu
OBn
-78oC
3.76 3.77a 3.77b
3.77a 3.78
80%
 
 
The yield could be increased by blocking the 1,4 addition of hydride, and many 
substrates and additives were not promising. Surprisingly, the key solution for this 
reaction was amount of solvent. When the doubled, 1,4 addition decreased from 2:1 to 
3:1. Tripling the amount of THF gave only the desired product, which gave the desired 
key intermediate 3.78 after just acidic work-up using 1-N HCl solution (Table 3.6). 
 
Table 3.5 Optimization for Reduction 
MeO O
CO2tBu
OBn
DIBAL
THF
MeO OH
CO2tBu
OBn
+
O
CO2tBu
OBn
-78oC
3.76 3.77a 3.77b  
entry THF/(100mg) 53:53-1 
1 5 ml 2:1 
2 10 ml 3:1 
3 15 ml 15:1 
 
Manipulation of the key developed intermediate 3.77a through a Michael type vinyl 
addition and triflate capturing was tried. However, we could not obtain the desired 
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triflate 3.79 but the ketone 3.80. Therefore, thermodynamic controlled enolate formation 
and triflate capturing without success (Scheme 3.29). Most adducts of the reaction was 
not identified and starting ketone 3.80 was recovered. 
 
Scheme 3.29 
O
BnO
CO2tBu
OTf
BnO
CO2tBu
i) CuI/TMEDA
vinylMgBr
THF/-78oC
ii) PhNTf2
O
BnO
CO2tBu
N
Tf2O, CCl4
Decompose
3.78 3.79
3.80  
 
The general method to make triflate 3.79 is a stepwise method via enolate capturing 
with TMSCl and subsequent TMS deprotection and enolate capturing with PhN(Tf)2.  
Upon subjection to this reaction sequence the desired triflate 3.79 was not provided 
(Scheme 3.30). The major polymerization problem  was  in the reaction. 
 
Scheme 3.30 
O
BnO
CO2tBu
OTMS
BnO
CO2tBu
1) CuI/TMEDA
vinylMgBr
THF/-78oC
2) TMSCl/HMPA 2) Tf2O
Polymerization
1) MeLi/THF
0oC
3.78 3.81  
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However, triflic anhydride delivered the desired triflate 3.79 with 24 % yield, but 
further optimization attempts were futile. 
 
Scheme 3.31 
O
BnO
CO2tBu
OTf
BnO
CO2tBu
2) Tf2O
24%
1) CuI/TMEDA
vinylMgBr
THF/-78oC
3.78 3.79  
 
Although the product was obtained in low yield, the desired key intermediate 3.79 
could be tested in the Heck reaction.  
 
 
E. Annulation of the Substituted Cyclohexene 
1. Heck Reaction Strategy 
Based on our original plan, the Heck reaction would be used as a key step for the 
annulation of the triflate 3.80 (Scheme 3.32). Heck reactions typically construct C-C 
bond at the least substituted carbon of the alkene. Therefore, the product of Heck 
reaction would be ketone 3.38.  
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Scheme 3.32 
3.80
+
Pd(OAc)2(PPh3)2(cat.)
HCO2H, DMF
80 oC
+
3.15
3.82
Piperidine
OTf
BnO
CO2tBu
BnO
CO2tBu
3.83BnO
CO2tBu
 
 
However, the gem-dimethyl group of the alkene will divert this reaction to the more 
substituted carbon to furnish the desired ketone 3.82. Therefore, we started the synthesis 
of the cyclohexene 3.15 for the Heck coupling (Scheme 3.33). 
Scheme 3.33 
O i.CuI, MeLi,THF
0oC
OTf
ii.TMSCl
80%
OTMS
82%
i.MeLi, THF
ii. PhN(Tf )2
3.84 3.863.85
CuI, MeLi,THF
0oC
3.15  
 
1-methyl-3,3-dimethyl cylclohex-1-ene 3.1563 was prepared by modified reported 
procedure. First, methylcuprate addition to-methyl-2-clohexenone 3.84 and capture with 
TMSCl delivered silylenol ether 3.85 in 82% yield. The silylenol ether 3.85 was 
transformed into vinyl triflate 3.86 with PhN(Tf)2 followed by methylcuprate addition to 
triflate 3.86 to deliver the desired key intermediate 3.15.  However, during the vinyl 
triflate transformation of silylenol ether 3.85, isomerization of olefin occurred affording 
a mixture of products.  
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OTf
80%
OTMS
i.MeLi, THF
ii. PhN(Tf)2
3.863.85
OTf
3.86a
+
 
 
After pursuing several unsuccessful trials, it became apparent our attention that an 
in-situ triflate capturing was promising (Scheme 3.34). After methylcuprate addition to-
methyl-2-clohexenone 3.84 and triflate capturing with PhN(Tf)2 delivered enol triflate 
3.86 was delivered in 80 % yield.   
Scheme 3.34 
3.84 3.86
CuI, MeLi,THF
0oC
O i.CuI, MeLi,THF
0oC
OTf
ii.PhN(Tf )2
80% 3.15  
 
With the desired cyclohexene 3.15 in hand, we tested the Heck reaction on a model 
system first. The synthesis of model enol triflate was pursued starting with the 
commercially available hexanone 3.87 (Scheme 3.35). Ketone 3.87 was methylated with 
LiHMDS/MeI in good yield. Treatment with triflic anhydride and a hindered pyridine 
base provided a mixture of enol triflate 3.89 in 10:1 ratio. The major thermodynamically 
controlled triflate 3.89 was separated from the minor 3.89a readily. 
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Scheme 3.35 
O O
O
LiHMDS
MeI/THF
O O
O
N tButBu
Tf2O
OTf
O O
CCl4
84%
43%
10:1
3.87 3.893.88
OTf
O O
3.89a
+
 
 
With both trflate and olefin in hand, the model Heck reaction was carried out 
(Scheme 3.36). However, planned Heck coupling under a variety of conditions giving 
only the reduced compound 15. 
 
Scheme 3.36 
OTf
+
Pd(OAc)2(PPh3)2
HCO2H, DMF
80 oC
Piperidine
OO
OO
OTf
+
Pd(OAc)2(PPh3)2
HCO2H, DMF
80 oC
Piperidine
OO
H
OO
3.15
3.91
3.903.89
3.15 3.89  
 
The Heck coupling was challenging reaction in our strategy is a challengeable and 
interesting reaction, our incapability to find suitable Heck coupling condition, this route 
was eventually abandoned and a more feasible strategy was pursued.  
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2. SN2′ Strategy 
A SN2′  reaction using metals such as zinc, copper and magnesium with proper 
electrophiles have shown to provide access to such intermediates. Therefore, the SN2′  
reaction was further explored toward the key intermediate 3.94 (Scheme 3.37). 
OTf
tBuO2C
BnO
O(o-DPPB)
tBuO2C
BnO
SnBu3
tBuO2C
BnO
3.80 3.92 3.93
3.94  
Limited quantities and scale-up problems of triflate 3.80 urged us a model study 
initially. After selecting a simple α-substituted triflate, the triflate 3.95 was continued to 
alkyl stannane 3.96 (Scheme 3.38). 
 
Scheme 3.38 
OTf SnBu3
i.LDA
iii.CuCN
ii.Bu3SnH
3.95 3.96  
 
However, the success in the model study did not prove useful in the real system 
(Scheme 3.39). Attempts to couple triflate 3.80 with cuprate reagent, shown  effective in 
sterically hindered settings, resulted in hydrolysis of the triflate 3.97. The steric 
hindrance of α-alkyl group was the problem cause since it blocked the approach of 
cuprate reagent and gave the ketone 3.97. 
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Scheme 3.39 
OTf
BnO
CO2tBu
SnBu3
BnO
CO2tBui.LDA
iii.CuCN
ii.Bu3SnH
O
BnO
CO2tBu i.LDA
iii.CuCN
ii.Bu3SnH
3.97 3.80 3.92  
 
Indeed, the bulky α ethyl t-butyl ester was also problematic in installing another 
bulky alkyl tin group place of the triflate 3.80. Reaction conditions using Pd (0) were 
also unsuccessful despite the promising result in the model study (Scheme 3.40). 
 
Scheme 3.40 
OTf
BnO
CO2tBu
SnBu3
BnO
CO2tBu
Pd(PPh3)4
Sn2(Bu3)2
3.80 3.92  
 
3. Addition/Dehydration Strategy 
Due to the difficulties encountered in the synthesis of the vinyl tin reagent 3.92, this 
route was eventually abandoned to establish a productive strategy. Allyzinc addition to 
the ketone 3.97 could be useful in constructing the quaternary carbon center in an 
asymmetric fashion based on work by Knochel64 (Figure 3.5). 
 
79 
O
OBn
ZnCl
H
tBuO2C  
Figure 3.5 Allyzinc Addition to the Ketone 3.97 
 
Therefore we set out to explore the allyl zinc addition reaction in the context of 
spongiolactone synthesis. The allyl zinc reagent required either the allyl chloride or allyl 
phosphate. Therefore, allyl chloride 3.99 synthesis began from allyl alcohol 3.98 with 
tetrachloromethane and triphenyl phosphate (Scheme 3.41). The reaction proceeded 
smoothly, but the desired allyl chloride 3.99 was not separable after much effort. The 
crude product was not stable even at low temperature, so we screened different reagent 
methods without success.  
 
Scheme 3.41 
OH
CCl4/PPh3
Ether
Cl
3.98 3.99  
 
 In light of the purification problem, the phosphate intermediate 3.101 may give 
increased stability. The phosphate was prepared by treatment with diethyl 
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chlorophospahtem 3.100 and triethyl amine but the phosphate was unstable to silica gel 
chromatography (Scheme 3.42). 
Scheme 3.42 
OH O
+
EtO
P
EtO
O
Cl
Et3N
P
O
OEt
OEt
CH2Cl2
3.98 3.100 3.101  
 
F. Construction of the [3.2.0] Bicyclo β-Lactone via a Diastereoselective NCAL 
Reaction 
We then turned to the construction of the [3.2.0] bicyclo β-lactone. Due to the 
inherent problems with the bulky α ethyl t-butyl ester was still problematic, if we could 
construct desired β-lactone first, we can shorten the reaction scheme and make the 
scheme more favorable manner from ketone 3.97 (Scheme 3.39).   
Scheme 3.43 
O
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Based on the revised strategy, the first t-butyl deprotection of ketone 3.97 using 
TFA/triethyl silane delivered acid 3.102 in almost quantitative yield (Scheme 3.44).  
 
Scheme 3.44 
CH2Cl2
TFA HO
O O
OBn
O
O O
OBn
Et3SiH
99%3.97 3.107  
 
Oxidative cleavage using OsO4/NaIO4 the previously described oxidative cleavage 
conditions proved detrimental to aldehyde 3.102 preparation. The reaction did not give 
any of the desired aldehyde 3.102. Therefore Ozonolysis reaction using dimethyl sulfide 
as a quenching reagent delivered the desired aldehyde 3.102 in moderate yield (Scheme 
3.45). Based on H1 NMR, the relative stereochemistry of cyclohexanone 3.102 was 
confirmed (j value of aldehyde was 10Hz). 
 
Scheme 3.45 
67%
CH2Cl2/MeOH
i)O3 HO
O O
OBn
O
HO
O O
OBn
ii)DMS
3.107 3.102  
 
The success of the aldehyde acid 3.102 synthesis, permitted further studies on the 
NCAL reaction. Although the NCAL reaction had never been attempted in such a 
complex setting before, pleasingly, it did not require much effort to find optimal 
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conditions for the NCAL reaction (Scheme 3.46). The NCAL reaction using aldehyde 
acid 3.102 provided β-lactone 3.103(or 3.103a) in excellent yield as an one single 
diastereomer.  
Scheme 3.46 
O
CO2H
O
BnO
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Even though we assumed a moderately diastereoselective NCAL reaction based on 
steric effect, it was encouraging that β-lactone formed as a single diastereomer. nOe 
experiments was used to confirm the β-lactone configuration. Although nOe analysis did 
not provide unambiguous evidence for the stereochemical assignment, it did confirm that 
there is no correlation between H2 and H4 (Figure 3.6), showing only existing relation 
ship between H2 and H1/H3/H9. Therefore we could assume that we have the desired 
diastereomer 3.103.  
 
OBn
O
H5
O
O H1
H2
H3
H3'
H4
H9'
H9
O
BnO
O
H9'
H9
H5
H4
O
H1 H2
 
Figure 3.6 Tentative Structure Analysis by nOe 
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G. Projected Completion of the Synthesis: Proposed Endgames 
The completion of the spongiolactone synthesis remains significant progress has 
been made and only a few steps remained (scheme 3.47). Allyl zinc addition could 
deliver the desired diastereomer 31 as expected from the transition state arrangement 
(Figure3.6). Hydrogenation with H2, Pd/C will provide the reduced with olefin and 
simultaneous deprotection of the benzyl group. Esterfication with 3-methyl propionyl 
chloride and Et3N would provide the primary ester over the tertiary alcohol. Finally, 
completion of spongiolactone would occur after dehydration using thionyl chloride. 
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CHAPTER IV 
CONCLUSIONS 
 
The recently isolated bacterial metabolites, belactosins A-C from a fermentation 
broth of Streptomyces sp. UCK14, uniquely contain a β-lactone dipeptide motif and 
exhibit anticancer activities.  
The TMAL process enabled a concise synthesis of (−)-belactosin C and derivatives 
employing a double diastereoselective process with chiral ketene acetals and a dipeptide 
glyoxamide or a novel tartrate-derived chiral glyoxylate. This strategy is unique in that 
the pharmacophoric β-lactone moiety of these proteasome inhibitors is constructed in a 
single step via the TMAL process leading to concise approaches to these novel 
proteasome inhibitors. Further biological evaluation of these and other belactosin 
derivatives including diastereomers and other structural derivatives showed that 
belactosins act as the dual inhibitors of the proteasome and the thioesterase domain of 
fatty acid synthase. 
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Spongiolactone which uniquely contains a cyclopentyl-fused β-lactone was isolated 
in 1986 from Spongi-onellagracilis. No synthesis has been reported for this compound. 
After many setbacks in the synthesis of spongiolactone, significant progress has been 
made. Based on Stork/Danheiser protocol, we could complete the synthesis of 
intermediate 3.78 via several steps from 1, 3-cyclohexanedione.  
After several manipulations such as Michael type addition with vinylcuprate, t-butyl 
deprotection with TFA and ozonolysis, synthesis of key intermediate 3.102 was 
completed for NCAL reaction. 
Importantly, NCAL process using aldehyde acid 3.102 also enabled a concise 
construction of [3.2.0]-bicyclo β-lactone as a single diastereomer with 64% yield and we 
could assume that we have the desired diastereomer 3.103 based on nOe experiment.  
This compound is the key structure in the racemic spongiolactone synthesis and 
several step remained to complete the synthesis. 
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CHAPTER V 
EXPERIMENTAL PROCEDURE 
General 
All reactions were carried out under nitrogen atmosphere in oven-dried (120 °C) 
glassware unless noted otherwise.  Tetrahydrofuran (THF) and diethyl ether (Et2O) were 
distilled immediately prior to use from sodium metal/benzophenone ketyl.  Methylene 
chloride (CH2Cl2, EM Science) and benzene (EM Science) were distilled from calcium 
hydride prior to use.  Methanol (MeOH, EM Science) was distilled from magnesium 
methoxide.  N,N-dimethylformide (DMF) was distilled from calcium hydride and stored 
over 4Å molecular sieves.  Triethylamine (Et3N, EM Science), diisopropylamine (Acros) 
and pyridine (EM Science) were distilled from calcium hydride immediately prior to use.  
The molarities indicated for organolithium reagents were established by titration with 
2,6-di-tert-butyl-4-methylphenol and 1,10-phenanthroline as indicator.  All other 
commercially obtained reagents were used as received.  
Optical rotations were measured with a JASCO DIP-360 digital polarimeter.  All 
optical rotation measurements were made at 23 °C in a 10 millimeter cell (length); 
concentration c is reported in g/100mL.  Infrared spectra were recorded with a Nicolet 
Impact 410 FTIR and a Bruker VERTEX 27 FTIR spectrometer.  
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1H NMR and 13C NMR spectra were recorded on a Unity Inova500 and Inova300 
spectrometer. 1H NMR chemical shifts are reported as δ values in ppm relative to 
tetramethylsilane (TMS, 0.00 ppm) or residual CHCl3 (7.27 ppm).  1H NMR coupling 
constants (J) are reported in Hertz (Hz), and multiplicities are indicated as follows: s 
(singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), bs (broad 
singlet), sext (sextet), apparent (app), dd (doublet of doublets).  Unless indicated 
otherwise, deuterochloroform (CDCl3) served as an internal standard (77.3 ppm) for all 
13C spectra.  Flash column chromatography was performed using 60Å Silica Gel (Baker, 
230-400 mesh) as a stationary phase as described by Still.65  Mass spectra were obtained 
on a VG analytical 70S high resolution, double focusing, sectored (EB) mass 
spectrometer at the center for Chemical Characterization and Analysis (Texas A&M).  
Enantiomeric excess (ee) was determined by GC (Hewlett-Packard 5880A gas 
chromatography) analysis using a 2,3-di-OAc-6-TBS β-CD column.  Thin layer 
chromatography (TLC) was performed using glass-backed silica gel 60F254 (Merck, 
250 µm thickness). 
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(S)-S-pyridin-2-yl 3-methylpentanethioate 2.46a 
OH
O
S
O
N
2,45a 2.46a  
To a stirred solution of acid 2.45a (1.24 g, 10.7 mmol) in CH2Cl2 (30 mL) was 
added oxalyl chloride (1.38 mL, 16.0 mmol) at 25 oC, and the reaction mixture was 
stirred for 2 h at 25 oC. The solvent was then evaporated under reduced pressure. To a 
stirred solution of the residual oil diluted with CH2Cl2 (20 mL) was added 2-thiopyridine 
(1.42 g, 12.8 mmol) in CH2Cl2 (20 mL) followed by Et3N (2.98 mL, 21.3 mmol) at 0 
oC.  
The reaction mixture was stirred for 2 h at 25 oC and then quenched with 1N HCl (30 
mL) and neutralized by washing with saturated NaHCO3 solution (30 mL x 2). The 
organic layers were combined and evaporated, and the resulting yellow oil was purified 
by flash chromatography on SiO2 (20% EtOAc/Hexanes) to afford thioester 2.46a (2.19 
g, 98 %) as a colorless liquid: [α]D
20 +8.2 (c=0.027, CHCl3). IR (thin film) 2953, 1702, 
1440, 1418 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.64 (m , 1H), 7.75 (m , 1H), 7.64 (m , 
1H), 7.31 (m , 1H), 2.73 (dd, J= 6.3, 14.7 Hz, 1H), 2.54 (dd, J= 7.8, 14.7 Hz, 1H), 1.96-
2.10 (m, 1H), 1.42-1.49 (m, 1H), 1.29-1.35 (m, 1H), 0.97 (d, J= 6.3 Hz, 3H), 0.91 (t, J= 
7.8 Hz, 3H) ; 13C NMR (125 MHz, CDCl3) δ 196.4, 151.9, 150.5, 137.4, 130.4, 123.7, 
51.3, 32.8, 29.5, 19.4, 11.5;  LRMS (ESI) Calcd. for C11H16NOS[M+H]+ : 210.0953. 
Found : 210.0967.(6.63 ppm) 
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(S,E)-2-(3-methyl-1-(triethylsilyloxy)pent-1-enylthio)pyridine 2.41a 
S
O
N
2.46a 2.41a
S
OTES
N
 
To a stirred solution of thioester 2.46a (8.00 g, 35.8 mmol), DMF (3.14 g, 43.0 
mmol) and Et3N (6.04g, 43.0 mmol) in CH2Cl2 (240 mL) was added LiHMDS (1.0M, 
82.6 mL, 82.6 mmol) at −78 oC. The reaction mixture was stirred for 30 min at −78 oC 
and then TESCl (12.02 mL, 71.6 mmol) was added dropwise to the reaction mixture. 
The reaction mixture was stirred for an additional 2 h at −78 oC and then quenched with 
pH 7 buffer solution (40 mL x 2). The organic layer was separated, dried over Na2SO4 
and evaporated. The resulting yellowish oil was purified by flash chromatography on 
SiO2 (10% EtOAc/Hexanes) to afford ketene acetal 2.41a (11.1 g, 96%) as a yellow oil : 
IR (thin film) cm-1; 2950, 2873, 1624, 1568 cm-1 ;  1H NMR (300 MHz, CDCl3) δ 8.40 
(m, 1H), 7.53 (m, 1H), 7.32 (m, 1H), 6.97 (m, 1H), 5.18 (d, J= 9.6, 1H), 2.58 (m, 1H), 
1.33-1.40 (m, 2H), 1.00 (d, J= 6.6 Hz, 3H), 0.93 (t, J= 7.5 Hz, 3H), 0.84-0.89 (m, 9H), 
0.60-0.68 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 160.9, 149.6, 138.7, 136.8, 130.5, 
122.3, 121.5, 119.9, 33.5, 30.1, 20.4, 12.3, 6.8;  LRMS (ESI) Calcd. for 
C17H29NOSSiLi[M+Li]+ : 330.1899. Found : 330.1939 (12.11ppm) 
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Fmoc-Ori(Boc)-OBn 2.53 
BocHN
O
NHFmoc
OH BocHN
O
NHFmoc
OBn
2.52 2.53  
To a stirred solution of Fmoc-Orn(Boc)-OH 2.52 (35.0 g, 77.00 mmol) and DMAP 
(1.0 g, 0.77 mmol) in CH2Cl (350 mL), at 0 
oC was added DIPEA (20.12 mL, 115.51 
mmol). To the resulting solution, was added CbzCl (13.25 mL, 92.41 mmol) at 0 oC. The 
mixture was stirred at 0 oC for 4 h, then washed with 1N HCl( 100 mL x 3), dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography on SiO2 (33% EtOAc/Hexanes) to afford benzyl ester 2.53 (45.0 g, 
100%) as a colorless solid. All spectroscopic data for this compound matched that 
reported previously30b 
 
Dipeptide 2.54 
BocHN
O
NHFmoc
OBn BocHN
O
NH
OBn
O
NHCbz
2.542.53
BocHN
O
NH2
OBn
 
To a stirred solution of benzyl ester 2.53 (41 g, 75.33 mmol)  in THF (200 mL), was 
added Et2NH (49 mL, 376.66 mmol) at room temperature. The reaction mixture was 
stirred for 12 h at 23 oC. The volatiles were evaporated and the residue was passed 
through a short pad of SiO2 flushing with 100% EtOAc to separate non-polar impurities. 
The organics were evaporated to afford the free primary amine (21.47 g, 88%) as a white 
solid. The resulting solid was taken up in CH2Cl2 (200 mL) and used directly in the next 
step. 
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To a stirred solution of Cbz-ala (17.77 g, 79.65 mmol) and HObt (9.87 g, 73.01 
mmol) in CH2Cl2 (100 mL), was added EDCI (13.96 g, 73.01 mmol) at 0 
oC. The 
resulting mixture was stirred for 30 min at 0 oC.  To the solution of the free amine was 
added TMP (20.63 g, 146.03 mmol), and the resulting suspension was added to the 
stirred reaction mixture. This was left to attain room temperature for 24 h and then was 
quenched by water, washed with 1N HCl (100 mL x 3) , and neutralized by concentrated 
NaHCO3 solution (100 mL x 2). The organic layer was separated and evaporated to give 
a crude residue, that residue was purified by flash chromatography on SiO2 (40% 
EtOAc/Hexanes) to afford dipeptide 2.54 (28.0 g, 84%) as a white solid. All 
spectroscopic data for this compound matched that reported previously30b 
 
(5S, 8S)-benzyl 5-methyl-3, 6, 13-trioxo-1-phenyl-2-oxa-4, 7, 12-triazapentadec-14-
ene-8-carboxylate 2.40 
ClH3N
O
NH
OBn
O
NHCbz
N
H
O
NH
OBn
O
NHCbz
O
2.40
 
To a stirred solution of amine salt (25.00 g, 53.89 mmol) and TMP (22.74 g, 134.7 
mmol) in CH2Cl2 (300 mL) was added acryloyl chloride (5.25 g, 64.7 mmol) at 0 
oC. The 
reaction mixture was stirred for 4 h at 0 oC and then quenched by slow addition of 1N 
HCl (100 mL) and neutralized by washing with saturated NaHCO3 solution (100 mL x 
2). The organic layer was separated and evaporated to give a crude solid, that was 
triturated with pentane to give the acrylamide peptide 2.40 (24.0 g, 93%). :  IR (thin 
film) 2937, 1796, 1728, 1665 cm -1; 1H NMR (500 MHz, CDCl3) δ 7.32-7.43 (m, 10H), 
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6.99 (s, 1H), 6.26 (d, J= 4.2 Hz, 1H), 6.04 (dd, J= 9.9, 16.6 Hz, 2H), 5.12 (m, 2H), 4.60 
(m, 1H), 4.28 (m, 1H), 3.27 (m, 2H), 1.82-1.96 (m, 1H), 1.61-1.73 (m, 1H), 1.42-1.58 
(m, 2H), 1.41 (d, J= 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 172.6, 171.7(2), 165.8, 
136.1, 135.1, 130.8, 128.7, 128.6(2), 128.5(2), 128.4(2), 128.2(2), 128.0, 126.5, 67.4, 
67.1, 52.1, 50.6, 38.7, 29.4, 25.4, 18.5; LRMS (ESI) Calcd. for C26H32N3O6[M+H]+ : 
482.2291 Found :482.26 (64ppm) 
 
(5S,8S)-benzyl 5-methyl-3,6,13,14-tetraoxo-1-phenyl-2-oxa-4,7,12-
triazatetradecane-8-carboxylate 2.55 
2.40
N
H
O
NH
OBn
O
NHCbz
O
N
H
O
NH
OBn
O
NHCbz
O
O
2.55
N
H
O
NH
OBn
O
NHCbz
O
OH
2.54
+
HO
 
Ozone was bubbled through a stirred solution of acrylamide 2.40 (5.0 g, 10.4 mmol) 
in CH2Cl2 (200 mL) and MeOH (1 mL) at −78 
oC until the blue color persisted, and the 
remaining ozone was removed by bubbling nitrogen through the solution. Dimethyl 
sulfide (3.1 mL, 41.6 mmol) was added and the mixture was left to attain 23 oC while 
stirring for 12 h. The solvent was evaporated under reduced vacuum and the resulting oil 
was purified by flash chromatography on SiO2 (50% CH2Cl2/acetone) to afford a mixture 
of hydrate 2.54 and glyoxylate 2.55 (3.0 g, 60%) as a white solid. This resulting mixture 
was dissolved into CH2Cl2 with 4 Å MS and stirred for 24 h at 23 
oC to give glyoxylate 
2.55. The resulting glyoxylate 2.55 was used directly in the next step without further 
purification. 
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Representative Procedure for TMAL Reaction under Normal Conditions (RP 1) 
Anhydrous ZnCl2 (1.2-2.0 equiv) was freshly fused under vacuum at ~0.5 mmHg 
and after cooling to ambient temperature, CH2Cl2 (appropriate volume to make final 
concentration of aldehyde in CH2Cl2 ~0.2 M) was added. The aldehyde (1.0 equiv) was 
then added neat or as a solution in CH2Cl2 at 25 
oC followed by thiopyridylketene acetal 
(1.1-1.2 equiv). The suspension was stirred for the indicated time, and then quenched 
with pH7 buffer and filtered through a celite pad. The organic layer was dried over 
Na2SO4, filtered, and concentrated in vacuo to afford the crude product which was 
purified by flash chromatography 
 
(5S,8S)-benzyl 5-methyl-3,6,13-trioxo-13-(4-oxo-3-methyloxetan-2-yl)-1-phenyl-2-
oxa-4,7,12-triazatridecane-8-carboxylate 2.57 
N
H
O
NH
OBn
O
O O
NHCbz
N
H
O
NH
OBn
O
O O
NHCbz
O
2.56 2.57a
N
H
O
NH
OBn
O
O O
NHCbz
O
+
2.57b  
 The β-lactone 2.57a/b (31.0 mg, 34%) as a mixture of diastereomers was prepared 
from glyoxylate 2.56 (23.7 mg, 0.15 mmol) and ketene acetal (5.3 mg, 0.18 mmol) 
according to RP 1 as a white solid.  IR (thin film) 3298 , 2940, 1831, 1730, 1656 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.27-7.41 (m, 10H), 6.70 (bs, 1H), 6.58 (bs, 1H), 5.36 (m, 
1H),  5.12-5.24 (m, 4H), 4.85 (d, J= 7.0 Hz, 1H), 4.63 (m, 1H), 4.26 (m, 1H), 4.00 (q, J= 
7.0 Hz, 1H), 3.25-3.31 (m, 2H), 1.90 (bs, 2H), 1.80-1.40 (m, 3H), 1.39 (d, J= 7.0 Hz, 
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3H), 1.27 (d, J= 8.0 Hz, 3H) ; 13C NMR (125 MHz, CDCl3) δ 172.5, 171.8, 169.7, 166.7, 
156.2, 136.4, 135.2, 128.9(2), 128.9(2), 128.8(2), 128.7, 128.5(2), 128.3, 71.8, 67.6, 
67.2, 52.0, 50.7, 50.2, 38.6, 29.6, 25.4, 18.6, 9.8; HRMS (ESI) Calcd. for 
C28H34N3O8[M+H]+ : 540.2346.  Found : 540.2324 (4.07ppm) 
 
(5S,8S)-benzyl 5-methyl-3,6,13-trioxo-13-(4-oxo-3-propyloxetan-2-yl)-1-phenyl-2-
oxa-4,7,12-triazatridecane-8-carboxylate 2.57-1 
N
H
O
NH
OBn
O
O O
NHCbz
N
H
O
NH
OBn
O
O O
NHCbz
O2.56 2.57-1a
N
H
O
NH
OBn
O
O O
NHCbz
O
+
2.57-1b
 
 β-Lactone 2.57-1a/b (63.0 mg, 34%) as a mixture of diastereomers was prepared 
from glyoxylate 2.56 (96.7 mg, 0.30 mmol) and ketene acetal 2.41b (11.6 mg, 0.36 
mmol) according to RP 1 as a white solid:  IR (thin film) 3308, 1838, 1724, 1661 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.27-7.41 (m, 10H), 6.74 (bs, 1H), 6.57(bs, 1H), 5.38 (s, 
1H),  5.12-5.24 (m, 4H), 4.63 (q, J= 5.0 Hz, 1H), 4.51 (d, J= 4.5 Hz, 1H), 4.25 (m, 1H), 
3.65 (m, 1H), 3.27 (m, 2H), 1.88 (m, 2H), 1.78-1.42 (m, 4H), 1.40 (d, J= 7.0 Hz, 3H), 
0.98 (t, J= 7.5 Hz, 3H) ; 13C NMR (125 MHz, CDCl3) δ 172.5, 171.8, 169.6, 167.9, 
156.0, 136.3, 135.2, 128.9, 128.9(2), 128.8(2), 128.7(2), 128.5(2), 128.3, 73.0, 67.6, 
67.3, 57.8, 52.0, 50.8, 38.6, 30.3, 29.6, 25.4, 20.1, 18.4, 13.8; HRMS (ESI) Calcd. for 
C30H38N3O8[M+H]+ : 568.2659.  Found : 568.2683 (4.22ppm) 
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(5S,8S)-benzyl 5-methyl-3,6,13-trioxo-13-(4-oxo-3-hexyloxetan-2-yl)-1-phenyl-2-
oxa-4,7,12-triazatridecane-8-carboxylate 2.57-2 
N
H
O
NH
OBn
O
O O
NHCbz
N
H
O
NH
OBn
O
O O
NHCbz
O
Hexyl
2.56 2.57-2
N
H
O
NH
OBn
O
O O
NHCbz
O
Hexyl
+
 
 The β-lactone 2.57 (24.0 mg, 31%) as a mixture of diastereomers was prepared 
from glyoxylate 2.56 (36.7 mg, 0.10 mmol) and ketene acetal (4.6 mg, 0.12 mmol) 
according to RP 1 as a white solid.  IR (thin film) 3291, 2923, 1836, 1713, 1650 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.27-7.41 (m, 10H), 6.72 (bs, 1H), 6.63(bs, 1H), 5.41 (bs, 
1H),  5.09-5.24 (m, 4H), 4.61 (m, 1H), 4.49 (t, J= 3.5 Hz, 1H), 4.27 (m, 1H), 3.61 (m, 
1H), 3.25 (m, 2H), 1.79-1.89 (m, 3H), 1.63-1.67 (m, 2H), 1.48-1.53 (m, 3H), 1.23-1.47 
(m, 5H), 1.40 (d, J= 7.0 Hz, 3H), 0.88-0.97 (m, 4H) ; 13C NMR (125 MHz, CDCl3) δ 
172.5, 171.8, 169.7, 168.3, 156.3, 137.3, 135.2,  128.9, 128.9(2), 128.8(2), 128.6(2), 
128.4, 128.2(2), 73.0, 67.7, 67.3, 58.0, 52.0, 50.7, 38.6, 31.6, 29.8, 29.5, 28.9, 28.3, 26.6, 
25.3, 22.7, 14.2; LRMS (ESI) Calcd. for C33H44N3O8[M+H]+ : 610.3128.  Found : 
610.3177 (8.02ppm) 
 
 
 
Representative Procedure for Acrylate Formation under Normal Conditions (RP 2) 
To a stirred solution of alcohol (1 equiv) and Et3N (1.25 equiv) in CH2Cl2 (0.4M) 
was added acryloyl chloride (1.2 equiv) at 0 oC. The reaction mixture was stirred for 4 h 
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at 0 oC and then quenched by slow additional 1N HCl and neutralized by washing with 
saturated NaHCO3 solution. The organic layer was dried over Na2SO4, filtered, and 
concentrated in vacuo to afford the crude product which was purified by flash 
chromatography. 
 
Acrylate 2.63 
OH O
O
2.632.62  
The acrylate 2.63 (2.01 g, 98%) was prepared from alcohol 2.62 (1.50 g, 12.28 
mmol) and acryloyl chloride (1.19 mL, 14.73 mmol) according to RP 2 and was isolated 
as a liquid following purification by column chromatography (10% EtOAc/hexanes).  
IR (thin film) 2985, 1721 cm -1; 1H NMR (500 MHz, CDCl3) δ 7.30-7.41 (m, 5H), 
6.47 (d, J= 17.4 Hz, 1H), 6.17 (dd, J= 10.5, 27.6 Hz, 1H), 6.01 (q, J= 6.6 Hz, 1H), 5.85 
(d, J= 10.5 Hz, 1H), 1.62 (d, J= 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.7, 
141.8, 131.0, 129.0, 128.8, 128.2, 126.3, 72.7, 22.5; LRMS (CI) Calcd. for C11H13O2 
[M+H]+ : 177.0916. Found:177.1 (47.4ppm) 
 
 
 
Acrylate 2.67 
Ph
HO NMe2
Ph
O NMe2
O  
99 
The acrylate 2.67 (4.46 g, 78%) was prepared from alcohol 2.66 (4.40 g, 24.55 
mmol) and acryloyl chloride (2.38 mL, 29.45 mmol) according to RP 2 and was isolated 
as a white solid following purification by column chromatography (25% 
EtOAc/hexanes).  
IR (thin film) 2974, 2940, 1728, 1407 cm -1; 1H NMR (500 MHz, CDCl3) δ 7.28-
7.37 (m, 5H), 6.47 (d, J= 17.0 Hz, 1H), 6.22 (dd, J= 10.5, 17.0 Hz, 1H), 6.02 (d, J= 5.0 
Hz, 1H), 5.89 (d, J= 10.5 Hz, 1H), 2.95 (m, 1H), 2.33 (s, 6H), 1.11 (d, J= 7.0 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 165.2, 139.9, 131.0, 128.6, 128.2, 127.5, 126.2, 75.4, 
63.8, 41.4, 9.; HRMS (ESI) Calcd. for C14H20NO2[M+H]+ : 234.1494. Found :234.1484 
(4.27ppm) 
 
Mono alcohol 2.74 
O
O OH
Ph
OH
Ph
O
O OH
Ph
OMe
Ph
2.73 2.74  
To a stirred solution of diol 2.73 (4.0 g, 12.7 mmol) and K2CO3 (5.3 g, 38.2 mmol) 
in acetone (100 mL) was added MeI (7.9 g, 127.2 mmol) at 25 
oC. The reaction was 
refluxed for 24 h and then cooled to 25 oC. The reaction mixture was filtered and 
evaporated to give a crude compound. The crude compound was purified by flash 
chromatography (25% EtOAc/hexanes) to give liquid (3.8 g, 90%).  : [α]D
20
 
−11.9 (c = 
0.16, CHCl3);  IR (thin film) 3446 , 2984, 2937 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.11-7.40 (m, 10H), 4.26 (dd, J= 6.5,  7.5 Hz, 1H), 4.04 (dd, J= 4.0, 7.5 Hz, 1H), 3.94 
100 
(d, J= 6.5 Hz, 1H), 3.87 (dd, J= 3.5, 7.5 Hz, 1H), 3.24 (s, 3H), 3.01 (d, J= 7.5 Hz, 1H), 
1.51 (s, 3H), 1.45 (s, 3H) ; 13C NMR (125 MHz, CDCl3) δ 141.3, 137.6, 128.9, 128.9, 
128.6, 128.1, 128.0, 126.7, 110.4, 85.0, 81.4, 80.7, 72.9, 57.1, 27.7, 27.6; HRMS (ESI) 
Calcd. for C20H24O4Li [M+Li]+ : 335.1835. Found : 335.1844 (2.69ppm) 
 
TBS ether 2.74b 
O
O OH
Ph
OH
Ph
O
O OH
Ph
OTBS
Ph
 
To a stirred solution of diol 2.73 (0.37 g, 1.16 mmol) in THF (10 mL) was added 
1.6M MeLi (0.73 mL, 1.16 mmol) at −78 oC. The mixture was allowed to reach 25 oC 
and  stirred for 30 min and then TBSCl (0.17g, 1.16 mmol) in THF(3 mL) was added at 
25 oC. The reaction mixture was quenched by slow addition of 1N HCl (10mL) and 
washed with saturated NaHCO3 (10mL x 2) solution. The organic layer was dried over 
Na2SO4, filtered, and concentrated in vacuo to afford the crude product. The resulting 
yellowish oil was purified by flash chromatography (16% EtOAc/hexanes) on SiO2 to 
afford TBS ether 2.74b (0.49 g, 99%). : [α]D
20
  + 58.4 (c = 0.43, CHCl3);  IR (thin film) 
3406 , 2912 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.22-7.40 (m, 10H), 4.44 (d, J= 4.5 Hz, 
1H), 4.37 (dd, J= 4.0, 7.5 Hz, 1H), 4.12 (dd, J= 5.0, 8.0 Hz, 1H), 4.07 (dd, J= 4.0, 7.5 
Hz, 1H), 3.01 (d, J= 7.5 Hz, 1H), 1.41 (s, 3H), 1.26 (s, 3H), 0.90 (s, 9H), 0.01 (s, 3H), -
0.16 (s, 3H) ; 13C NMR (125 MHz, CDCl3) δ 141.1, 140.6, 128.6, 128.2, 128.0, 128.0, 
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127.7, 126.8, 110.2, 81.6, 80.8, 75.4, 73.6, 27.8, 27.4, 26.1, 18.5, 14.4 ; HRMS (ESI) 
Calcd. for C25H36O4SiLi [M+Li]+ : 435.2543. Found : 435.2547 (0.91ppm) 
 
Benzyl ether 2.74c 
O
O OH
Ph
OH
Ph
O
O OH
Ph
OBn
Ph
 
To a stirred solution of diol 2.73 (0.34 g, 1.08 mmol) and K2CO3 (0.53 g, 3.82 
mmol) in acetone (10 mL) was added BnBr (0.14 g, 1.19 mmol) at 25 
oC. The reaction 
was refluxed for 15 h and then cooled to 25 oC. The reaction mixture was quenched with 
1N HCl (50 mL), and washed with saturated NaHCO3 solution (50 mL x 2). The organic 
layer was dried over Na2SO4, filtered, and concentrated in vacuo to afford the crude 
product. The resulting crude oil was purified by flash chromatography on SiO2 to afford 
TBS ether 2.74c (0.41 g, 94%). The crude compound was purified by flash 
chromatography (20% EtOAc/hexanes).  : [α]D
20
 +54.4 (c = 0.62, CHCl3);  IR (thin film) 
3452 , 3025, 1985, 2873 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.09-7.37 (m, 15H), 4.56 
(d, J= 12.0 Hz, 1H), 4.21-4.21 (m, 2H), 4.01-4.11 (m, 2H), 4.05 (d, J= 6.0 Hz, 1H), 2.88 
(d, J= 6.5 Hz, 1H), 1.48 (s, 3H), 1.35 (s, 3H) ; 13C NMR (125 MHz, CDCl3) δ 140.6, 
137.8, 128.5, 128.4, 128.3, 128.3, 128.0, 127.8, 127.7, 127.6, 126.5, 81.0, 80.9, 80.5, 3.3, 
70.3, 27.6, 27.1; LRMS (ESI) Calcd. for C26H28O4Li [M+Li]+ : 411.2148. Found : 
411.2123 (6.08ppm) 
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Acrylate 2.75 
O
O OH
Ph
OMe
Ph
O
O O
Ph
OMe
Ph
O2.74 2.75  
To a stirred solution of alcohol 2.74 (16.01 g, 28.7 mmol) and Hunig’s base (6.02 g, 
34.5 mmol) in CH2Cl2 (300 mL) was added acryloyl chloride (2.79 g, 34.5 mmol) at 0 
oC. 
The reaction mixture was stirred for 12 h at 25 oC and then quenched with 1N HCl (100 
mL), and washed with saturated NaHCO3 solution (100 mL x 2). The organic layer was 
dried over Na2SO4, filtered, and concentrated in vacuo to afford the crude product, which 
was purified by flash chromatography (10% EtOAc/hexanes) give a white solid 2.75 
(10.1 g, 83%) : [α]D
20 
−15.4 (c=0.25, CHCl3);  IR (thin film) 2978 , 2925, 1727 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.11-7.41 (m, 10H), 6.46 (dd, J= 1.5, 17.4 Hz, 1H), 6.17 (dd, 
J= 10.5, 20.1 Hz, 1H), 5.87 (dd, J= 1.5, 10.5 Hz, 1H), 5.03 (d, J= 3.9 Hz, 1H), 4.16 (m, 
2H), 3.86 (d, J= 6.0 Hz, 1H), 3.22 (s, 3H), 1.52 (s, 3H), 1.49 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 165.2, 137.6, 137..4, 131.5, 129.0, 128.9, 128.6, 128.5, 128.0, 127.4, 
110.9, 84.9, 80.7, 80.0, 75.1, 57.0, 27.9, 27.5;  LRMS (ESI) Calcd. for C23H26O5Li 
[M+Li]+  : 389.1940. Found : 389.1974 (8.73ppm) 
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The acrylate 2.75b (0.32 g , 73%) was prepared from free alcohol 2.74b (0.40g, 
0,93 mmol) and acryloyl chloride (0.090 mL, 1.20 mmol) according to RP 2 as a white 
solid following purification by column chromatography (10% EtOAc/hexanes).  
 [α]D
20 + 69.1 (c=0.75, CHCl3);  IR (thin film) 2933, 2855, 1732, 1403 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.19-7.40 (m, 10H), 6.48 (dd, J= 2.5, 28.5 Hz, 1H), 6.23 (dd, 
J= 17.5, 28.5 Hz, 1H), 5.88 (dd, J= 2.5, 17.5 Hz, 1H), 5.53 (d, J= 8.0 Hz, 1H), 4.31 (t, 
J= 6.5 Hz, 1H), 4.28 (dd, J= 8.0, 12.0 Hz, 1H), 4.07 (dd, J= 7.5, 12.5 Hz, 1H), 1.44 (s, 
3H), 1.41 (s, 3H), 0.93 (s, 9H), 0.02 (s, 3H), -1.81 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 165.3, 140.9, 137.7, 131.5, 129.7, 128.7, 128.6, 128.3, 128.1, 127.6, 110.7, 81.9, 79.6, 
76.1, 75.5, 27.8, 27.5, 26.1, 18.5, 14.4;  HRMS (ESI) Calcd. for C28H38O5SiLi [M+Li]+  : 
489.2649. Found : 489.2641 (1.6ppm). 
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Acrylate 2.75c 
O
O OH
Ph
OBn
Ph
O
O O
Ph
OBn
Ph
O  
The acrylate 2.75c (0.42 g, 72%) was prepared from free alcohol 2.74c (0.51 g, 1.26 
mmol) and acryloyl chloride (0.15 mL, 1.89 mmol) according to RP 2 as a white solid 
following purification by column chromatography (8% EtOAc/hexanes).  
 [α]D
20 + 51.1 (c=0.14, CHCl3); IR (thin film) 3446 , 2984, 1720, 1403 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.04-7.60 (m, 15H), 6.45 (dd, J= 1.0, 17.5 Hz, 1H), 6.18 
(ddd, J= 1.5, 10.5, 17.5 Hz, 1H), 5.86 (dd, J= 1.5, 10.5 Hz, 1H), 5.30 (dd, J= 2.5, 5.0 Hz, 
1H), 4.52 (d, J= 12.0 Hz, 1H) 4.28-4.30 (m, 1H), 4.16 (dd, J= 1.5, 14.0 Hz, 1H), 4.10-
4.12 (m, 1H), 3.86 (dd, J= 3.0, 5.0 Hz, 1H), 1.49 (s, 3H), 1.43 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 165.3, 138.2, 137.9, 137.3, 131.6, 128.9, 128.7, 128.6, 128.6, 128.5, 
128.2, 128.1, 127.8, 127.5, 111.1, 81.0, 80.9, 79.7, 76.0, 70.5, 27.7;  HRMS (ESI) Calcd. 
for C29H30O5Li [M+Li]+  : 465.2253. Found : 465.2267. (3.01ppm) 
 
Representative Procedure for Oxidative Cleavage under Normal Conditions (RP 3) 
To a stirred solution of acrylate (2.70 g, 7.06 mmol) in THF /H2O(6/4, 100 mL) was 
added OsO4 (0.05 equiv) and NaIO4 (4equiv)  at 0 
oC.  The reaction mixture was stirred 
for 2 h at 0 oC, then water was added and the mixture was extracted with Et2O. The 
organic layer was separated, dried over Na2SO4, filtered, and concentrated in vacuo to 
afford the crude product, which was purified by flash chromatography to afford a 
mixture of hydrate and desired glyoxylate. The resulting mixture of hydrate and 
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glyoxylate was dissolved into CH2Cl2 with 4 Å MS and stirred for 24 h at 23 
oC to give 
glyoxylate. The resulting glyoxylate was used directly in the next step without further 
purification. 
 
Glyoxylate 2.76 
O
O O
Ph
OMe
Ph
O
O
O
O O
Ph
OMe
Ph
O  
The glyoxylate 2.76 (2.67 g, 98%) was prepared from acrylate 2.75 (2.70 g, 7.06 
mmol), using OsO4 (0.03 g, 0.35 mmol) and NaIO4 (8.39 g, 28.2 mmol) according to RP 
3 and was isolated as a white solid following purification by column chromatography 
(50% EtOAc/hexanes):   
 
Glyoxylate 2.76b 
O
O O
Ph
OTBS
Ph
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O O
Ph
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O  
The glyoxylate 2.76b (0.98 g, 98%) was prepared from acrylate 2.75b (1.0 g, 2.07 
mmol), using OsO4 (0.01 g, 0.12 mmol) and NaIO4 (2.51 g, 8.46 mmol) according to RP 
3 and was isolated as a white solid following purification by column chromatography 
(50% EtOAc/hexanes).  
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The glyoxylate 2.76c (0.99 g, 98%) was prepared from acrylate 2.75c (1.0 g, 2.18 
mmol), using OsO4 (0.03 g, 0.35 mmol) and NaIO4 (8.4 g, 28.2 mmol) according to RP 3 
and was isolated as a white solid following purification by column chromatography 
(100% EtOAc). 
 
β-Lactone 15 
O
O O
Ph
OMe
Ph
O
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The β-lactone 2.77a (5.0 mg, 5%) was prepared from glyoxylate 2.76 (79.7 mg, 
0.20 mmol) according to RP 1 and was isolated as a white solid: [α]D
20 
−71.2 (c=0.38, 
EtOAc); IR (thin film) 2917 , 1843, 1733 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.14-7.37 
(m, 10H), 5.20 (d, J= 5.5 Hz, 1H), 4.67 (d, J= 4.5 Hz, 1H), 4.19 (dd, J= 6.0, 7.5 Hz, 1H), 
4.03 (dd, J= 6.0, 6.0 Hz, 1H), 3.69 (d, 5.5 Hz, 1H), 3.65 (dd, J= 4.5, 7.5 Hz, 1H), 3.16(s, 
3H), 2.00 (m, 1H), 1.62 (m, 1H), 1.48 (s, 3H), 1.45 (s, 3H), 1.33 (m, 1H), 1.07 (d, 7.0 
Hz, 3H), 0.92 (t, 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 169.0, 167.6, 137.5, 136.1, 
129.2, 128.9, 128.5, 127.8, 127.7, 111.0, 84.2, 80.8, 79.4, 69.3, 62.9, 57.1, 33.8, 27.8, 
27.5, 27.0, 16.6, 11.2; HRMS (ESI) Calcd. for C28H34O7Na [M+Na]+ : 505.2202. Found : 
107 
505.2212.(1.97ppm) 
The β-lactone 2.77b (30.0 mg, 30%) was prepared from glyoxylate 2.76 (79.7 mg, 
0.20 mmol) according to RP 1 and was isolated as a white solid: [α]D
20 
−51.6 (c=0.56, 
EtOAc).  IR (thin film) 2917 , 1843, 1733 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.16-7.39 
(m, 10H), 5.17 (d, J= 5.5 Hz, 1H), 4.68 (d, J= 4.5 Hz, 1H), 4.19 (dd, J= 5.0, 6.5 Hz, 1H), 
4.06 (dd, J= 6.0, 6.0 Hz, 1H), 3.75 (d, 6.0 Hz, 1H), 3.49 (dd, J= 4.5, 9.0 Hz, 1H), 3.16(s, 
3H), 1.98 (m, 1H), 1.59 (m, 1H), 1.48 (s, 3H), 1.47 (s, 3H), 1.22 (m, 1H), 1.10 (d, 7.0 
Hz, 3H), 0.94 (t, 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 168.7, 167.5, 137.4, 136.1, 
129.2, 129.0, 128.9, 128.9, 127.9,127.6, 111.1, 84.5, 80.9, 79.5, 77.1, 70.3, 63.4, 57.1, 
34.4, 27.9, 27.6, 27.5, 16.4, 11.1; HRMS (ESI) Calcd. for C28H34O7Na [M+Na]+ : 
505.2202 Found : 505.2214 (1.98ppm) 
 
β-lactone acid 2.24 
O
O O
Ph
OMe
Ph
O
O
O Me
HH
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O
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To a solution of β-lactone 2.77a (80.3 mg, 0.16 mmol) in THF (3.0 mL) was added 
Pd/C and HCO2H (2.0 mL). The mixture was stirred under an atmosphere of H2 (rubber 
balloon) for 17 h. The catalyst was filtered off through a pad of cotton wool and the 
solvent was removed under reduced pressure to give an oily liquid, which was purified 
by flash chromatography give β-lactone acid 2.24 (21.2 mg, 77%) was obtained as an 
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oily liquid: [α]D20 +3.1 (c = 0.59, CHCl3).  All other data matched that previously 
reported.30c 
 
N-CBZ-O-Bn protected belactosin C 2.58c 
2.24
O
O
H
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Coupling of dipeptide 2.42 (34.8  mg, 0.075 mmol) and β-lactone acid 2.24 (15.2 
mg, 0.088 mmol) was accomplished according to the published procedure 10c employing 
DCC (24.8 mg, 0.12 mmol) and HOBT (16.2 mg, 0.12 mmol) in 1.0 mL EtOAc/H2O 
(1:1 ratio) to provide amide 2.58c (23.4 mg, 53%) as a colorless solid: [α]D20 +3.2 (c = 
0.72, CHCl3). All other data matched that previously reported.30b 
 
(−)-Belactosin C  
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H
N
O
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H H  
Deprotection of N-CBZ-O-Bn belactosin C 2.58c (6.3 mg, 0.01 mmol) was 
accomplished by the method of Armstrong10a employing Pd/C (1 mg) in 5 
mLTHF/HCO2H (3:2) for 15 h to provide belactosin C (2.9 mg, 81%) as a glassy solid 
following purification by column chromatography(5% MeOH/CHCl3): [α]D
20 
−8.1 (c = 
0.92, H2O). 1H NMR (500 MHz, CDCl3) δ 4.92 (d, J= 4.5 Hz, 1H), 4.19 (dd, J= 5.0, 6.5 
Hz, 1H), 3.84 (dd, J= 4.5, 7.5 Hz, 1H), 3.30 (t, J= 7.0 Hz, 2H), 2.00-2.09 (m, 1H), 1.77-
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1.83 (m, 1H), 1.65-1.74 (m, 1H), 1.51-1.61 (m, 2H), 1.49-1.59 (m, 1H), 1.32 (m, 1H), 
1.03 (d, 7.0 Hz, 3H), 0.92 (t, 7.5 Hz, 3H): All other data matched that previously 
reported. 30b 
 
t-Butyl ester 3.73 
O O O O
tBuO2C
3.70 3.73  
To a stirred solution of 60% NaH (0.42 g, 10.70 mmol) in DMF (20 mL) was added 
diketone 3.70 (1.0 g, 8.92 mmol) and t-butyl acrylate (1.44 g, 9.81 mmol) at 25 oC. The 
reaction was heated to 85 oC for 24 h and then cooled to 25 oC. The reaction mixture was 
quenched with 1N HCl (50 mL), neutralized by washing with saturated NaHCO3 solution 
(50 mL x 2). The organic layer was separated, dried over Na2SO4, filtered, and 
concentrated in vacuo to afford the crude product. The resulting crude oil was purified 
by flash chromatography on SiO2 (15% EtOAc/hexanes) to afford t-butyl ester 3.73 (3.8 
g, 90%).;  IR (thin film) 1723, 1727 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.34 (s, 1H), 
2.45-2.48 (m, 6H), 2.34 (t, J= 6.5 Hz, 2H), 1.92 (q, J= 6.5 Hz, 2H), 1.45 (s, 9H) ; 13C 
NMR (125 MHz, CDCl3) δ 199.0, 178.2, 173.7, 115.0, 82.7, 36.9, 34.6, 29.6, 28.3(3), 
20.7, 16.9; LRMS (APCI) Calcd. for C13H21O4[M+H]+ : 241.1440. Found : 241 
(597ppm) 
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Vinylogous methyl ester 3.71 
O OMe
tBuO2C
O O
tBuO2C
3.73 3.71  
To a stirred solution of diketone 3.73 (1.0 g, 4.16 mmol) and K2CO3 (1.13 g, 4.99 
mmol) in acetone (20 mL) was added dimethyl sulfate (0.39 g, 4.16 mmol) at 23 
oC. The 
reaction was stirred for 12 h at 23 oC. The reaction mixture was quenched with water (20 
mL) and extracted by ethyl acetate (20 mL x 2). The organic layer was separated, dried 
over Na2SO4, filtered, and concentrated in vacuo to afford the crude product. The 
resulting solid was purified by flash chromatography on SiO2 (15% EtOAc/hexanes) to 
afford enol ether 3.71 (0.98 g, 94%) ;  IR (thin film) 2980,1724, 1642, 1611 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 3.82 (s, 3H), 2.52-2.62 (m, 4H), 2.22-2.38 (m, 4H), 1.96-
2.04 (m, 2H), 1.44 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 198.1, 173.3, 172.6, 118.2, 
79.9, 55.4, 36.5, 34.5, 28.4(3), 25.1, 21.1, 18.1; HRMS (ESI) Calcd. for C14H22O4Li 
[M+Li]+ : 261.1678. Found : 261.1681 (1.1 ppm) 
 
Diester 3.74a 
3.74a3.71
O OMe
tBuO2C
O OMe
tBuO2C
OMe
O  
To a stirred solution of hexenone 3.71 (120 mg, 0.47 mmol) in THF (5 mL) at −78 
oC was added 1.0M LiHMDS (0.47 mL, 0.47 mmol). After stirring at −78 oC for 30 min, 
methyl cyanoformate (0.04 mL, 0.52 mmol) was added and the reaction was stirred at 23 
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oC for 12 h. The reaction mixture was quenched with pH 7 buffer (20mL) and extracted 
with ethyl ether (20 mL x 2). The combined organic layer was evaporated to give a crude 
oil that was purified by flash chromatography on SiO2 (30% EtOAc/Hexanes) to afford 
methyl ester 3.74a (91 mg, 61%) : IR (thin film) 2696, 2949, 1723, 1643, 1604 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 3.84 (s, 3H), 3.75 (s, 3H), 3.32-3.38 (m, 1H), 2.76-2.82 (m, 
1H),  2.55 (q, J= 8.0 Hz, 3H), 2.30-2.50 (m, 1H),  2.25 (t, J= 8.5 Hz, 3H), 1.43 (s, 9H) ; 
13C NMR (125 MHz, CDCl3) δ 192.3, 173.1, 172.5, 117.5, 80.1, 55.5, 52.5, 51.6, 34.3, 
31.2, 28.3(3), 23.5, 23.4, 18.3; LRMS (ESI) Calcd. for C16H25O6 [M+H]+ : 313.1651. 
Found : 313.1734 (26.5 ppm) 
 
Benzyl ether 3.76 
3.763.73
O OMe
tBuO2C
O OMe
tBuO2C
OBn
 
To a stirred solution of diisopropyl amine (0.27 mL, 1.95 mmol) in THF (5 mL) was 
added 2.45 M n-BuLi (0.83 mL, 2.03 mmol) at −78 oC. After stirring at 0 oC for 30min, 
the solution was cooled to −78 oC and then cyclohexenone 3.73 (0.45 g, 1.77 mmol) in 
THF (5 mL) was added. After stirring at −78 oC for 30 min, benzyl chlormethyl ether 
(0.31 mL, 0.52 mmol) was added to the reaction mixture, and stirring was continued for 
12 h at −20 oC. The reaction mixture was then quenched with pH 7 buffer (20 mL) and 
extracted by ethyl ether (20 mL x 2). The combined organic layer was evaporated to give 
a crude oil, which was purified by flash chromatography on SiO2 (30% EtOAc/hexanes) 
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to afford benzyl ether 3.76 (0.45 g, 78%) ; IR (thin film) 1725, 1683, 1606 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.24-7.40 (m, 5H), 4.53 (AB, J= 12.0 Hz, 2H),  3.90 (dd, J= 
4.0, 10.0 Hz, 1H), 3.81 (s, 3H), 3.57 (dd, J= 9.0, 10.0 Hz, 1H), 2.66 (dt, J= 5.0, 17.5 Hz, 
1H), 2.47-2.57 (m, 4H), 1.82-1.90 (m, 1H), 1.43 (s, 9H) ; 13C NMR (125 MHz, CDCl3) δ 
197.5, 173.3, 172.4, 138.7, 128.6(2), 127.9, 127.8(2), 117.9, 79.9, 73.4, 70.0, 55.3, 45.2, 
34.5, 28.4(3), 24.3, 24.1, 18.2; HRMS (ESI) C22H30O5Li [M+Li]+ : 381.2253. Found : 
381.2262 (2.36 ppm) 
 
Cyclohexenone 3.78 
3.783.76
O OMe
tBuO2C
OBn
O
OBn
CO2tBu
 
To a stirred solution of benzyl ether 3.76 (0.14 g, 0.37 mmol) in THF (15 mL) was 
added DIBAL (0.07 mL, 0.37 mmol) at −78 oC. After stirring at −78 oC for 1 h, The 
reaction mixture was quenched with Rochelle salt solution (20 mL) and stirred for an 
additional 2 h while allowing to reach ambient temperature. Water (20 mL) was then 
added, the mixture extracted with ethyl ether (20 mL x 2). The organic layer was 
combined, washed with 1N HCl (20mL x 5) and then evaporated to give the crude 
product as a yellow oil. The resulting yellowish crude compound was purified by flash 
chromatography on SiO2 (15% EtOAc/hexanes) to afford cyclohexenone 3.78 (0.45 g, 
78%) ; IR (thin film) 2978, 2863, 1726, 1673, 1365 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.24-7.37 (m, 5H), 6.71 (s, 1H),  4.55 (AB, J= 12.0, 2H), 3.44 (dd, J= 2.0, 6.5 Hz, 2H), 
113 
2.64-2.70 (m, 1H), 2.44-2.60 (m, 3H), 2.34-2.37 (m, 3H), 2.08-2.18 (m, 1H), 1.70-1.80 
(m, 1H), 1.42 (s, 9H) ; 13C NMR (125 MHz, CDCl3) δ 199.3, 172.6, 147.2, 138.7, 138.2, 
128.7(2), 128.0, 127.9(2), 80.4, 73.5, 72.9, 37.5, 37.3, 34.6, 28.4(3), 26.3, 25.7 ; HRMS 
(ESI) C21H28O4Li [M+Li]+ : 351.2148. Found : 351.2145 (0.8 ppm) 
 
Enol triflate 3.79 
3.793.78
OTf
OBn
CO2tBu
O
OBn
CO2tBu
 
To a stirred solution of CuI (82 mg, 0.43 mmol) in THF (5 mL) was added TMEDA 
(0.065 mL, 0.43 mmol) at 0 oC. After stirring at 0 oC for 10 min, the reaction mixture 
was cooled to −78 oC and then 1M vinyl magnesium bromide (0.87 mL, 0.87 mmol) was 
added. The reaction mixture was stirred at −78 oC for 30 min and then enone 3.78 (100 
mg, 0.29 mmol) in THF (1mL) was added to the reaction mixture. After stirring at −78 
oC for 2 h, Tf2O (0.15 mL, 0.87 mmol) was added. After stirring at −78 
oC for 2 h, the 
reaction mixture was quenched with 1N HCl (10 mL), extracted with Et2O (20 mL x 2), 
and washed with saturated NaHCO3 solution (10 mL x 2). The organic layer was 
separated, dried over Na2SO4, filtered, and concentrated in vacuo to afford the crude 
product. The resulting yellowish oil was purified by flash chromatography on SiO2 (15% 
EtOAc/hexanes) to afford triflate 3.79 (33 mg, 23%) as a colorless oil : IR (thin film) 
3437 , 1717, 1634 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.26-7.37 (m, 5H), 5.80-5.89 (m, 
1H), 5.31 (d, J= 11.5 Hz, 1H), 5.18 (d, J= 17.0 Hz, 1H), 4.45 (d, J= 3.5 Hz, 2H), 3.34-
114 
3.50 (m, 3H), 2.27-2.58 (m, 5H), 2.11-2.24 (m, 3H), 1.60-1.78 (m, 1H), 1.45 (s, 9H) ; 
13C NMR (125 MHz, CDCl3) δ 172.3, 138.5, 135.6, 128.6(2), 127.9, 127.8(2), 120.2, 
95.0, 80.6, 73.5, 73.4, 72.1, 53.5, 37.8, 36.5, 32.8, 32.3, 29.9, 29.0, 28.4(3); LRMS (ESI) 
Calcd. for C24H32F3O6S [M+H]+ : 505.1872. Found : 505.1409 (91.6 ppm) 
 
Cyclohexanone 3.80 
3.803.79
O
OBn
CO2tBu
O
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CO2tBu
 
To a stirred solution of CuI (82 mg, 0.43 mmol) in THF (5 mL) was added TMEDA 
(0.065 mL, 0.43 mmol) at 0 oC. After stirring for 10 min, the reaction mixture was 
cooled to −78 oC and then 1M vinyl magnesium bromide (0.87 mL, 0.87 mmol) was 
added. The reaction was stirred for 30 min and then enone 3.78 (100 mg, 0.29 mmol) in 
THF (1 mL) was added to the reaction mixture. After stirring at −78 oC for 2 h, the 
reaction mixture was quenched with pH 7 buffer (20 mL) and extracted with Et2O (20 
mL x 2). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to 
afford the crude product. The resulting yellow oil was purified by flash chromatography 
on SiO2 (20% EtOAc/hexanes) to afford cyclohexanone 3.80 (87 mg, 81%) : IR (thin 
film) 2968 , 2851, 1728, 1700 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.25-7.40 (m, 5H), 
5.55 (dt, J= 10.0,  17.0 Hz, 1H), 5.16 (dd, J= 1.0, 10.0 Hz, 1H), 5.02 (d, J= 17.0 Hz, 
1H), 4.47 (AB, J= 12.0 Hz, 2H), 3.56 (dd, J= 3.0, 9.0 Hz, 1H), 3.30 (dd, J= 7.0, 9.0 Hz, 
1H), 2.26-2.45 (m, 5H), 2.05-2.20 (m, 2H), 1.90-1.96 (m, 1H), 1.75-1.80 (m, 2H), 1.63-
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1.76 (m, 1H), 1.44 (s, 9H) ; 13C NMR (125 MHz, CDCl3) δ 211.4, 173.4, 139.3, 138.7, 
128.6(2), 127.8, 127.8(2), 117.9, 80.2, 73.4, 72.7, 52.3, 51.9, 41.7, 41.5, 33.3, 30.5, 
28.4(3), 22.2 ; LRMS (ESI) Calcd. for C23H32O4Li [M+Li]+ : 379.2461. Found : 
379.2423 (10.01 ppm) 
 
Acid 3.107 
3.1073.80
O
OBn
CO2H
O
OBn
CO2tBu
 
To a stirred solution of ester 3.80 (110 mg, 0.29 mmol) and Et3SiH (0.62 mL, 0.62 
mmol) in CH2Cl2 (5 mL) was added TFA (0.067 mL, 0.59 mmol) at 0 
oC. After stirring at 
25 oC for 16 h, the reaction mixture was evaporated to give a crude oil. The resulting 
yellow oil was purified by flash chromatography on SiO2 (25% EtOAc/hexanes) to 
afford acid 3.102 (92 mg, 96%) : IR (thin film) 2931, 2867, 1711 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.26-7.40 (m, 5H), 5.55 (dt, J= 10.0,  17.0 Hz, 1H), 5.16 (dd, J= 1.5, 
10.0 Hz, 1H), 5.03 (dd, J= 1.5, 17.0 Hz, 1H), 4.47 (AB, J= 12.0 Hz, 2H), 3.56 (dd, J= 
3.5, 9.0 Hz, 1H), 3.32 (dd, J= 6.5, 9.5 Hz, 1H), 2.45-2.48 (m, 1H), 2.42-2.46 (m, 2H), 
2.29-2.35 (m, 3H), 2.09-2.13 (m, 1H),1.81-1.98 (m, 1H), 1.80-1.89 (m, 2H),1.61-1.70 (m, 
1H) ; 13C NMR (125 MHz, CDCl3) δ 211.2, 178.9, 138.8, 138.3, 128.3(2), 127.6, 
127.5(2), 117.8, 73.1, 72.3, 51.9, 51.5, 41.4, 41.2, 31.4, 30.2, 21.6 ; HRMS (ESI) Calcd. 
for C19H25O4[M+H]+ : 317.1753. Found : 317.1742 (3.47ppm) 
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Acid aldehyde 3.102 
O
OBn
CO2H
O
O
OBn
CO2H
3.107 3.102  
Ozone was bubbled through a stirred solution of acid 3.107 (90 mg, 0.24 mmol) in 
CH2Cl2 (3 mL) and MeOH (0.1 mL) at −78 
oC until the blue color persisted, and the 
remaining ozone was removed by bubbling nitrogen through the solution. Excess 
dimethyl sulfide (1.0 mL) was added and the mixture was warmed to 25 oC for 12 h. The 
solvent was evaporated under reduced pressure and the resulting oil was purified by 
flash chromatography on SiO2 (50% EtOAc/hexanes) to afford aldehyde acid 3.102 (63 
mg, 67%) as a colorless oil: IR (thin film) 3446 , 2931, 2860, 1711 cm-1; 1H NMR (500 
MHz, CDCl3) δ 9.68 (s, 1H), 7.20-7.40 (m, 5H), 4.46 (AB, J= 12.0 Hz, 2H), 3.45-3.51 
(m, 1H), 3.30-3.37 (m, 1H),  2.75 (t, J= 10.0 Hz, 1H), 2.33-2.58 (m, 7H), 2.12-2.21 (bd, 
J= 13.0 Hz, 1H), 1.85-1.94 (m, 1H), 1.55-1.69 (m, 1H) ; 13C NMR (125 MHz, CDCl3) δ 
209.5, 200.5, 178.7, 137.5, 128.4(2), 127.8, 127.7(2), 73.2, 72.4, 58.9, 46.6, 40.4, 31.5, 
38.6, 29.1, 21.9; LRMS (ESI) Calcd. for C18H21O5 [M-H]+ : 317.1389. Found: 317.1322 
(21.13 ppm) 
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NCAL Reaction 
3.102 3.103
O
OBn
CO2H
O
O
OBn
O
O
H
H
 
To a slurry of Mukaiyamas reagent (109 mg, 0.31 mmol) and triethy amine (0.09 
mL, 0.63 mmol) in  CH2Cl2(2 mL)at 23 
oC was added via syringe pump a solution of 
aldehyde-acid 3.102 (50 mg, 0.15 mmol) in 1.0 mL of CH2Cl2 over 1 h at 23 
oC.  After 
the addition was complete, the reaction was stirred for an additional 48 h.  The solvent 
was then removed in vacuo, and the dark red residue was purified by flash 
chromatography on SiO2 (50 % EtOAc/hexanes) to afford β-lactone 3.103 (32 mg, 71%) 
as a white solid: IR (thin film) 2940, 2896, 1825, 1711 cm-1 ; 1H NMR (500 MHz, 
CDCl3)  7.26-7.40 (m, 5H), 5.07 (dd, J= 3.5, 3.5 Hz, 1H), 4.55 (dd, J= 4.0, 16.0 Hz, 2H), 
3.92 (dd, J= 3.5, 8.0 Hz, 1H), 3.54-3.66 (m, 2H), 2.79-2.85 (m, 1H), 2.45-2.48 (m, 2H), 
2.33-2.38 (m, 1H), 2.16-2.20 (m, 2H), 1.85-1.91 (m, 1H), 1.69-1.81 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ 209, 170.6, 138.0, 128.4(2), 127.8, 127.5(2), 75.9, 73.2, 71.7, 54.3, 
51.8, 50.1, 40.5, 36.9, 30.3, 24.6; HRMS (ESI) Calcd. for C18H20O4Li[M+Li]+:  
307.1522.  Found: 307.1507 (4.88ppm)  
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